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ABSTRACT 
It has been recorded that women respond to tricycl ic antidepress ives 
with a greater incidence of antichol inergic side effects than men do, 
particularly women taking an exogenous source of oestrogen. 
The aim of this study was to investigate the influence that ethinyl 
oestradiol and Premarin R had on the metabol ism of a number of tricyclic 
antidepressives, and also the influence they had on the binding abil ity 
of microsomes to imipramine. 
Rat hepatocyctes and microsomes were used . Detection techniques 
used were High Pressure Liquid Chromatography and Spectrophotometry 
respectively. 
In addition to these studies, a study of the anticholinergic 
activity of Nomifensine, tri Gycl ic antidepressives and their derivatives 
was performed on a rat jujenum. 
Results conclusively showed that ethinyl oestradiol had a marked 
influence on the metabolism of the tricyclic antidepressives studied. 
Premarin R had I ittle, if any influence. However, both ethinyl 
oestradiol and Premarin R affected the binding of microsomes to 
imipramine, but ethinyl oestradiol had the greater effect. 
The parent compound in each case exhibited a higher pAZ value. 
Results indicate that a possible explanation for the increased 
anticholinergic side effect is due to an inhibition of the metabol ism 
of the tricycl ic ant idepressives by oestrogen . 
- x i i-
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LITERATURE REVIEW 
SECTION 
CLASSIFICATION OF MENTAL DISORDERS 
Mental disorder can be divided into two main groups (Merital 
1 
Scientific) 
Neurosis and 
Psychosis 
1.1 Neurosis 
Neurotic people have exaggerated, normal reactions. Because 
of poor inter-personal relationships and due to the fact that they are 
incapable of handl ing their own personal emotional confl icts, these 
people regard themselves as inadequate and they consequently become 
anxious. 
This anxiety or fear may either present as an anxiety neurosis 
or the patient might process it in one of the following ways; 
a) He may act in an obsessive complusive fashion, in other words, 
his daily routine is occupied with numerous small and comparatively 
unimportant rituals. This rigid way of existence prevents proper 
development of his or her personal ity and if such an individual 
cannot execute these rituals, he develops fear, anxiety, and 
depression (here depression is a symptom of the neurosis). 
b) The other alternat ive is hysteria . These individuals do not 
experience any anxiety, but whenever ci rcumstances of anxiet y do arise 
they si mp I y d i ssoc i ate themse 1 ves and escape into a wor 1 d of fantasy. 
-2-
1.2 Psychosis 
Psychotic patients have no insight into their problems and 
they I ive in a world of their own which is dominated by 
hallucination and delusion. 
This distortion of reality is one of the main differences 
between neurotic and psychotic people. As a group, neurotics are 
able to recognise real ity but the psychotics have no insight or very 
I ittle insight into their condition at all. 
1.2. I Organic Psychoses 
Organic psychoses are caused by organic pathology of the brain, 
trauma, tumours, or diminished cerebral blood supply (as in senil ity 
and arteriosclerosis). 
1.2.2 Functional Psychoses 
In these cases no obvious underlying physical abnormal ity can 
be detected. Functional psychoses are divided into schrzophrenla 
and affective psychosis . 
1.2.2. I Schizophrenia 
Schizophrenia accounts for approximately one fifth of patients 
currently residing in mental institutions, and is still one of the 
least understood conditions in psychiatry. In its most typical 
for m, it consists of a slow deteriorationoftheentirepersonality 
which often manifests itself at a period of adolescence. It 
involves a great part of mental I ife and expresses itself in disorder 
of feel ing, of conduct, of thought and in an increasing withdrawal of 
interest from the environment. 
are recognised : 
The following types of schizophrenia 
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a) Simple Schizophrenia 
b) Paranoid Schizophrenia 
c) Heberphrinic Schizophrenia 
d) Catatonic Schizophrenia 
But most cases are not clear cut and considerable overlap can occur. 
1.2.2.2 Affective Psychoses 
Affective psychoses are those conditions in which there is 
alteration of mood to such a degree as to cause a serious distress 
or disruption of normal life. 
J .2.2.2. I MENTAL DEPRESSION 
Classification 
There is no satisfactory classification of the depressive 
disorders. There are three main types of depression without 
adverting to an elaborate classification 2 • The firs tis the 
reactive depression. It is by far the most common and is typified 
by the grief reaction. Manic depressive psychosis is the second 
type. The third is involutional melancholia. 
REACTIVE DEPRESSION 
Grief - grieving occurs in response to a loss. The loss may be 
real, as in the death of a spouse, or imaginative or even symbol ic. 
The typical acute grief reaction comprises five characteristics. 
I. An intense subjective sensation of mental pain accompanied 
by a feel ing of exhaustion. 
2. Preoccupation with the image of the deceased. 
3. A sense of guilt concerning the relationship to the deceased. 
4. An inexpl icable and unwarranted hostil ity towards friends and 
relatives. 
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5. A loss of the usual pattern of conduct. Bereaved individuals 
are unable either to initiate or to arrange their daily 
affairs and tend to perform routine tasks in an automatic and 
uninterested fashion. 
The natural course of the normal grief reaction extends over a 
period of four to twelve weeks, by which time most of these five 
characteristics begin to abate, and within a few more months normal 
activities are resumed. 
There are many variations of the grief reaction. 
a. Pathologic Grief 
The most frequent one is prolongation of the reaction; i.e., 
there is no sign of resolution by the end of a three month period. 
Mothers who have lost young children tend to suffer for a long 
period of time, and the elderly who have lost a spouse of many years 
may never recover completely . Patients with a history of previous 
depressive episodes may also remain in mourning for longer periods. 
b. Delayed or Postponed Grief 
Often in an attempt to sustain the morale of others or to 
avoid the unpleasant spectacle of mourning, the patient may show 1 ittle 
or no reaction to the loss for weeks or months. 
may go into a major depression. 
Other Forms of Reactive Depression 
Then an individual 
Depressed patients seldom, if ever, express feel ings of sadness 
or despair without mentioning physical concomitants suchas the ease 
with which they tire, their loss of appetite, reduced interest in life 
and love, and trouble in fall ing asleep or in premature awakening . 
Therefore,whenever these symptoms become manifest in the course of 
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psychosis is divided into three subtypes, manic, depressive and 
circular. 
Manic-depressive psychosis is an illness largely confined to 
the middle and later adult years. Not many patients develop their 
first attack prior to their fiftieth year, and the peak age of onset 
is between fifty-five and sixty-five for both sexe s. The disease 
is two or three times more frequent among females. It is more 
common in individuals of Jewish and Irish heritage and occurs more 
frequently among those of upper socioeconomic strata. The manic 
forms tend to occur at an earl ier age than the depressi ve, but at 
any age episodes of depression are far more frequent than are 
episodes of mania. 
Cl inical Picture 
The depressive phase may develop into a full-blown picture 
within a surprisingly few days. The patient is apathetic and 
despondent, with reduced energy for mental and physical activity. 
There is a lack of interest in all pleasurable activity. Over-
whelmed by feel ings of helplessness and indecisiveness, patients 
become increasingly dependent and incapable of act ing on their own 
behalf . In despair, they express the desire for death and may 
become suicidal with very 1 ittle warning. Combination of weakness, 
easy fatigue, anorexia, insomnia, and loss of 1 ibido may dominate 
the c l ini cal picture and may therefore simulate several medical 
diseases. At its worst the illness takes the form of a depressi ve 
sleep as the patient becomes mute and indifferent to nutritional 
needs and neglectful even of bowel and bladder function s. The 
condition at this ti me resembles catatonia. The patient must be 
fed and vital functions tended until therapy brings about an 
improvement. 
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The manic phase is, in most ways, the mirror opposite of 
the depressed phase. Patients are hyperactive with increased 
appet 'ite and sexual drive. Wi th ami n i mum of sleep they awake in the 
morning filled with joy and expectation. They appear to possess 
great drive and confidence, yet lack the ability to carry out their 
plans . Their threshold for paranoid thinking is low, which makes 
them sensitive and suspiciou s. They tend to neglect themselves to 
the point of poor personal hygiene. 
First attacks of either depression or mania last an average 
of 6 mon ths if untreated. Modern therapy can reduce this by more 
than half. Attacks tend to be longer in older age groups. 
INVOLUTIONAL MELANCHOLIA 
This is a severe depression of psychotic proportions which occurs 
in the involutional phase of 1 ife. It is characterized by agitation, 
insomnia and a profound sence of worthlessness. Multiple physical 
complaints, some of which may be delusional in nature, generally 
accompany the condition. 
There appears to have been a steady increase in the prevalence 
of this disorder over the last 50 years. This probably refl ects the 
growing awareness of the condition by the lay population and the 
appreciation that such an entity as "middle-l ife depression" exists 
and can be treated rather than an actual increased evidence. Three 
times as many females as males fall victim to it . There is no known 
cause for this sexual distribution, but some ha ve speculated that 
just as many men are depressed but that it is manifested as 
a lcohol ism in these patients. Women are more apt to develop signs of 
involutional melanchol ia between the ages of fifty-one and sixty, 
whereas men usually fall prey to it some 5 to 10 years later. Unl ike 
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manic-depressive psychosis, this depression is more common in low 
socioeconomic categories. 
CI inical Picture 
The condition is characterized by increased irritability, 
insomn ia, psychomotor restlessness, easy fatigue, loss of interest 
in sexual and gustatory pleasures, and an ever-mounting worry about 
health. These manifestations occur over one or more years before 
the cl inical picture is complete. As time passes, the individual's 
life narrows to a single-minded concern about physical deterioration, 
mental decl ine, or both. Before long, every conversation comes to 
balance on the fulcrum of symptons, no matter how hard the patient 
may try to avoid that topic. 
In contrast to the physical inactivity and mental slowness of 
the depressed manic-depressive patient, the priQcipal behavioural 
manife·station of involutional melanchol ia is agitation. As a 
consequence these patients usually pace restlessly about the room 
and have great difficulty sitting still. Furthermore, they tend to 
be over talkative and vexed in their manner of expression. 
SCHEMATIC SUMMARY 
/ 
NEUROSIS 
\ 
MENTAL ILLNESS 
/ / 
PSYCHOSIS 
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SECTION 2 
CLASSIFICATION OF PSCYCHOTROPIC DRUGS 
2.1 Neuroleptics: drugs of which the main therapeutic effect is 
on psychosis but may benefit other types of psychi.atric disorders. 
In addition they usually produce extra pyramidal effects, such as 
tremor and rigidity. 
a} Phenothiazines: e.g. Chlorpromazine 
b} Thioxanthines: e.g. Thiothixene 
c} Butyrophenones: e.g. Haloperidol 
p} Diphenylbutylpiperidines: e.g. Pimozide 
e} Reserpine derivatives 
2.2 Anxiolytic Sedatives: substances that reduce pathological 
anxiety, tension and agitation, without therapeutic effect on 
disturbed cognitive or perceptual processes. These drugs usually 
raise the convulsive threshold and do not produce extrapyramidal or 
autonomic effects. They may produce drug dependence. 
a} Propanedioles e.g. Meprobamate 
b} Benzodiazepines e.g . Chlorodiazepoxide 
c} Barbiturates: e.g. Amulobarbitone sodium 
2.3 Antidepressives: drugs effective in the treatment of 
pathological depressive states. 
a} Monoami ne oxidise inhibitors: e.g. Phenylzine 
b} Tricycl i c and Tetracyclic compounds: e.g. Imiprami ne & 
Mianserin 
c} Other: e.g. Nomifensine 
2.4 Psychostimulants: drugs that increases the level of alertness 
and motivation. 
a} Amphetamine : Dexamphetamine 
b} Caffeine 
- I 1-
SECTION 3 
ANTIDEPRESSIVE DRUGS 
The successful introduction of chlorpromazine into therapy in 
1953 marked the beginning of the era of psycho pharmacol ogy 3. In 
the fol lowing years, scores of derivatives, mainly phenothiazines 
and other tricycl ic compounds , were synt hesized in the search 
for new psychotropic drugs. One of these compo unds, imipramine, 
was relea sed to be cl inically tested for its presumed antihistaminic 
sedative and above all neuroleptic activities . The new compound 
demonstrated a distinct antidepressive action as observed and 
formulated by the psychiatrist Kuhn. 
Scores of imipramine derivatives as well as totally different 
structures were tested as antidepressives;only about a dozen have 
remained in therapeutic use. 
Closely related compounds, could be divided into two groups. 
Imipramine (a dibenzazepine clerivative) and amitriptyl ine (a 
dibenzocycloheptane derivative). The other non structural 
related antidepressives although not monoamine oxidase (MAO) 
inhibitors could be classified into monocycl ic, bicycl ic, tricycl ic 
and tetracycl ic antidepressives. 
3. I Tricycl ic Antidepressives 
Imipramine, amitripty l ine and other closely related compounds 
are the drugs currently used for the treatment of depression. 
Because of their structure (Table I) they are often referred to as 
tricycl ic antidepress ives. 
3. I • I Pharmacology 
The general pharmacology of these drugs has been reviewed,·5. 
TABL[ 
IMIPRAMINE AND OTHER DIBENZAZEPINE ANTIDEPRESSIVES 
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S DOTHIEPIN H CH-CH 2-CH 2-N 
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-.......:::: 
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The pharmacological profile of tricycl ic antidepressives is 
characterized by a multitude of actions which apparently do not 
relate with cl inical antidepressive action. 
3.1.1.1 Central Nervous System 
Many of imipramine's effects, behavioural or otherwise, resemble 
those of the phenothiazines. 1 n bot h an i ma 1 s and norma 1 humarys , 
sedation and decreased psychomotor activity are noted. There is no 
stimulatory or mood changing action except in depressed patients 
suggesting a pecul iar specificity towards a pathologic state rather 
than an extension of pharmacological effects. 
Effect on Sleep The tricycl ic antidepressives occasionaly have been 
used as hypnotics because of their sedative property. Although this 
effect may be useful in the initial therapy of a depressed patient 
", ith sleep loss,therr general use for hypnosis is not recomme nded. 
3.1.1.2 Action on Brain Amines 
The action of the tricycl ic antidepressives on the metabol ism of 
catecholamines and indoleamines in the brain has contributed 
si gnificantly to the "biogenic amines hypothesis" of depression. The 
amines of primary interest are serotonin and noradrenal ine. Tricycl ic 
antidepressives have no significant effect on dopamine. All tricycl ic 
antidepressives block the re-uptake of noradrenal ine by adrenergic 
nerve terminals. The demethylated analogues are OIore-potent in this 
action, whereas the ~ethylated drugs are more potent in the blockade 
of serotonin re-uptake. The exact relationship of these effects to 
the actions of the tricyclic antidepressives in hu ma n depression is 
not known . 
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3.1. 1 .3 Cardiovascular System 
Tricycl ic antidepressives have marked effect on the cardiovascular 
system even in therapeutic doses 6 • There is an increased tendency for 
arrhythmias to develop in patients and there have been several reports 
of unexpected deaths due to this cause 7 These adverse reactions may 
be related to the blockade of amine re-uptake by these drugs and the 
resultant high concentration of noradrenal ine in cardiac tissue. 
Orthostatic hypotension is commonly observed with tnerapeutic doses 
possibly due to increase of noradrenal ine in vasomotor centre. My-
ocardial infarction during the course of treatment has been attributed 
to imipramine administration. Tachycardia is a common finding. The 
most prominent ECG change observed following the use of imipramine 
consists of inversion or flattening of the T waves. 
3.1.1.4 Respiration 
In man, imipramine in cl inical doses produces 1 ittle effect on 
respiration. Respiratory depression has been observed fol lowing 
poisoning with imipramine and with amitriptyl ine. 
3.1.1.5 Antichol inergic Effects 
. . . h 15.8.9.10.11 The tricyclic antldepressives possess perlp era and 
1 • .• .. 5.9,10,11 centra antlmuscarlnlc activity 
The side effects commonly seen occurring In 5z - 30~ of patients, 
include dry mouth, drowsiness or sedation and constipation. Less 
common side effects include extra pyramidal symptoms (usually mild 
and consisting of tr.emor, but sometimes akathisia or gait disturbance) 
blurred vision, postural hypotension, sweating and tachycardia. 
Urinary retention has been rare. Some investigators have reported 
instances of parasthesia, notable weight gain, exciteme nt and 
leukopaenia and thrombocytopenlo' . . These and other infrequent 
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side effects are to be expected from tricycl ic antidepressives. 
MECHANISM OF ANTIMUSCARINIC ACTION 
Parasympathetic Nervous System 
This system consists of three outflows of pregangl ionic fibres from 
the CNS and their postgangl ionic connections. The regions of central 
origin are the midbrain, the medu lla oblongata and the sacral part of 
the spinal cord. The parasympathetic . system . has its terminal 
gangl ia very near to the organs innervated and thus is more discrete 
and 1 imited in its discharge of impulses than the sympathetic nervous 
system. The parasympathetic system is concerned primarily with the 
fu nctions of conservation and restoration of ene rgy rather than with the 
expenditure of energy. It slows the heart rate, lowers the blood 
pressure, stimulates the gastrointestinal movements and secretions, 
aids absorption of nutrients, protects the retina from excessive 
12 1 ight, and empties the urinary bladder and rectum. 
Acetylchol ine Receptors 
Acetylchol ine receptors of the peripheral nervous system of 
vertebrates are classified into two major categories. There are 
nicotinic receptors, activated by nicotine and inhibited by d-
tubocurarine, which are found in autonomic gangl ia, skeletal muss le 
and in the central nervous system, and there are muscarinic 
receptors, activated by L(+) muscarine and inhibited by atropine, 
which are found in smooth muscle, cardiac muscle, gang 1 ia, brain 
and glands. There are also acetylchol ine · receptors in mammalian ·hiain that 
have been found to exhibit mixed nicotinic - muscarinic 
13 pharmacology . 
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Influence af Structure an Affinity and Intrinsic Activity 
A receptar must perfarm twa functians; firstly, it must recagnise 
chemical features af the drug which are apprapriate far farming a 
campi ex; secandly, the farmat ian af this drug-receptar camplex may 
lead to. the initiatian af a physialagical change in the cell (i.e., 
the effect af aganists) ar it may nat (i.e., the effect af antaganists). 
In the latter case, its act ian is revealed in preventing the act ian af 
an aganist, ar af a physialagically .· (eleased trans mitter. An aganist 
therefare will shaw affinity far the receptar and intrinsic activity, 
whereas an antaganist will anly shaw affinity and no. intrinsic 
acti v it y. 
Whi Ie it is highly prabable that an endagenaus aganist exists far 
each receptar, in practice the aganist may nat be knawn and in any 
case the specificity af a receptar is nat uniquely determined by a 
single I igand but rathe r by the range af chemical structures that 
inte ract with it. A receptar type is therefare defined by structure 
activity relatianships. 
In the case af muscarinic receptar s campetitian between aganists 
and radio. acti ve label led antaganists ha s shawn that all the 
specifically baund antagon ist ca~ be displaced by a suffiCient 
. f . 14 cancentratlan a aganlst . In ard er to. initiate an act ian it is 
necessary t hat the aganist shauld be able to. change the cha r acter af 
the recept a r in same way. It seems t o. t:e inescapabl y ident ified wi th a 
canfarmatian al cha~ge. 
Specu lating an the nature af the receptors far acetylchal ine in 
the terminal s ynapse af i ts parasymathe tic nerves studies have 
yielded the fallowing infarmatian: 
(I) The interaction af the ammonium graups or their equivalents .. \lith 
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the receptors con tributes to the affinity and is essential for the 
intrinsic activity, e.g., Acetylchol ine . 
CH 3 
.1 
H,C-C-O-H,C-H2C-N-CH 3 
<l 1 
CH3 
(2) Alkyl substitution on the ammonium or amino groups leads to a 
loss of the intrinsic activity. Also the affinity decreases, but it 
increases again when the alkyl or aralkyl substituents become large 
enough to contribute to the affinity on additional receptor parts, e.g. I. 
Atropine. 
HOH,C 0 CH,-CH CH z 
" II 1 +' CH-C-O-CH N-CH 3 < >/ !Hz-CII CH z 
e.g., 2. Isopropamide 
(3) Introduction of a B-methyl group in chol ine leads to an I'. and d 
compound. The I'.-compo und is about as active as acetylchol ine; 
the d-compound is much less active. e.g., Methachol ine • . 
CH 3 CH 3 
~ 1 + I H3 C-C-O-CH-CH z- N-CH 3 
B Cl \ 
(4) The ester group in the drug molecule or its equivalent 
contributes to the affinity. It is not essential for the intrinsic 
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activit y o It appears to facilitate the induction of the stimulus 
and therefore contributes to the intrinsic activity, e.g. Acetyl-
chol in e . 
CH 3 
+ I 
H3C-C-O-H2C-H2C- N-CH 3 8 \ 
CH 3 
(5) Substitution of an alkyl or phenyl group and other rings on 
the acetic acid moiety of acetylchol ine and analogous substitutions 
in other parasympathomi meti cs result in a loss in the intrinsic 
activity and a loss in the affinity. The loss in affinity may be 
compensated for, however, when binding energy is gained on 
additional receptor parts by large substituents, e.g . Propanthel ine 
Practically all acetylchol inolytics have in common a positively 
charged group with some larger more or less planar structure at a 
suitable distance, and one or two phenyl or heterocyl ic rings. 
The length of the chain between the positively charged g roup and the ring 
structure is less specific; it must have a certain length. usually 
h f · . d' 15 tree to our InteratomiC Istances. 
Figure shows structure and specificity for mime tics and 
lytics. 
Figure 1 
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Specific Part 
i 11 
Non-specific Part 
f j) 
C-C-O-C-C-N-C-C-C 
~ ~ (> 
Mimetics 
Highly Specific 
Lytics : Less Specific 
Lytics : Non-specific 
Mimetics and lytics, structure and specificity. 
Model for the relation between mimetics, lytics 
containing the specific structure of the mimetic 
and lytics without this specific structure. 
Table 2 shows lytics chemically related to mimetics 
Table 2 
Relations in the Chemical Structure of ~imetics and Different Types 
of Lytics 
MIMETICS 
Non Specific, Muscarinic and Nicotinic 
e.g . Acetylchol ine 
CH3 
H H / 
I I + CH3-C-O-C-C- N-CH 3 
II I I \ o H H 
CH 3 
Muscarine Specific 
e.g. Muscarine 
-20-
Tab 1 e 2 cont. 
LYTICS 
Very Specific for Mu scarinic Receptors 
i --
, 
'Recept-, 
, or 
:Lyt i cs 
I ~ -'" 
,_----1 
, 2' , 
~on - specific Multi-Potent Antagonist 
-....... ~ 
- - - Re';;p~~r I 
Lytic 
---
........... - - I 
--
Receptor Mimetic 
Receptor Lytic 
e .g . J Propantheline 
e.g . 2 Atropine 
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Table 2 cont 
e.g. I Isopropamide 
e.g. 2 Imipramine 
From the theories put forward by Ariens 15 one can postulate 
the possible mechanism that tricyclic antidepressives have as 
antichol inergic agents. Because of the structure of tricycl ic 
andidepressives they would be expected to act as non specific 
Iytics, soonewould expect them to show antihistaminic effects as 
well. In fact they do have this property, therefore they can be 
called multipotent antagonists. 
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3.1.2 Metabo 1 ism 
The metabol ism of only a few drugs has been investigated as 
thoroughly as that of imipramine. There are a number of reasons for 
this. Imipramine is a widely used drug which, soon after its 
introduction, was found to form therapeutically active metabol ites. 
Owing to several points of attack on the imipramine molecule, the 
drug undergoes metabol ism by multiple pathways leading to some 
thi rty metabol ites. Imipra mi ne has therefore become a model drug 
for the study of a complex drug metabol ic situation. 
Table 3 shows the metabol ically vulnerable groups or bonds 
of the imipramine molecule and a 1 ist of metabol ites known to date. 
Of more than twenty atom groups of the molecule, only six are 
known to be points of metabol ic attack 3,16. Thus all biotransformations 
of imipramine result in peripheral molecular changes only, leaving the 
tricycl ic nucleus intact. All metabol ites still belong to the one 
chemical family of benzazepine derivatives. The number of metabol ites 
far surpasses the nu mber of metabolically vulnerable positions. This 
is because two or more positions can be attacked simultaneously or in 
sequence leading to the formation of combination metabol ites e.g. 
20H des imipramine, which is both demethylated and hydroxylated. The 
number of theoretically possible combinations exceeds thirty. However, 
certain combinationsof metabol ic attack exclude each other. Thus, 
hydroxylated N-oxides or metabolites hydroxylated both in 2 and 10 
positions, have never been found. There are vast differences in the 
amountsof individual metabol ites produced. The major imipramine 
metabol ites in most species are des imipramine, 2 hydroxy-imipramine, 
2 hydroxy- desipramine, and O-glucuronidcs of the latter two 
hydroxylated metabol ites. 
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TABLE 3 
Metabol ical ly Vulnerable ~arts of the Imipramine Molecule 
and Metabol ites of Imipramine 
GAe 
• 
METABOLITE 
2 Hydroxyimipramine 
Desmethyl imipramine, desipramine 
2 Hydroxyimipramine glucuronide 
2 Hydroxydesmethyl imipramine 
2 Hydroxydesipramine glucuronide 
Desdimethylimipramine 
Imipramine N-oxide 
Iminodibenzyl 
2 Hydroxyiminodibenzyl 
10 Hydroxyimipramine 
10 Hydroxydesimipramine 
10 Hydroxydesdimethyl imipramine 
10 Hydroxyiminodibenzyl 
10 Hydroxyimipramine glucuronide 
10 Hydroxydesimipramine glucuronide 
10 Hydroxydesdimethyl imipramine glucuronide 
10 Hydroxyiminodibenzyl glucuronide 
2 Hydroxydesdimethyl imipramine 
2 Hydroxydesdimethyl imipramine glucuronide 
2 Hydroxyiminodibenzyl glucuronide 
Desmethyl imipramine-N-glucuronide 
N-Hydroxydesmethyl imipramine 
N-Hydroxydesdimethyl imipramine 
ABBREV I AT! ON 
2-0H-IM 
DMI 
20H-IM-G 
20H-DMI 
20H-DMI-G 
DDMI 
IMNO 
IDB 
20H-IDB 
lO-OH-IM 
lO-OH-DMI 
10-OH-DDMI 
lO-OH-IDB 
10-OH-IM-G 
10-OHDMI-G 
lO-OHDDMI-G 
1 O-OH-I DB-G 
2-0H-DDMI 
2-0H-DDMI-G 
20H-IDB-G 
DMI-N-G 
DMI-N-OH 
DDMI-N-OH 
ACH, al iphatic hydroxylation; ARH aromatic hydroxylation, GAC 
glucuronic acid conjugation; NOX N-oxidation; OND oxidative 
N-d~nethylation; OSD oxidative side-chain dealkylation . 
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The predominant pathways leading to the major metabol ites of 
imipramine are represented schematically in Table 4 . Oxi dative-N 
demethylation may occur in two steps transforming imipramine to 
its seconda ry des imipramine and pri mary desdimethyl imipramine 
amine analogues. Oxidative side chain dealkylation, leading to the 
formation of iminodibenzyl, may be the same type of reaction which is 
directed towards the non basic nitrogen atom. Formation of imino-
benzyl may also occur non enzymatical ly. Aromatic hydroxy1ation "in 
position 2 is a major pathway, while aliphatic hydroxylation in 
position 10 is of minor importance. The phenol ic and alcohol ic 
metabol ites resulting from the latter pathways serve as substrates 
for the important pathways of O-glucuronidation, which is often so 
efficient that few unconjugated hydroxylated metabol ites can be 
detected. The pathway of N-glucuronidation can apply to secondary 
and primary amines only. In addition to N oxidation of imipramine, 
two pathways have been shown to apply to the N-oxide formed. 
N-oxide reduction efficiently leads back to imipramine, while N-
oxide demethylation, a non oxidative process leads to dimethyl imipramine. 
N-oxidation of the secondary and primary amine analogues results in the 
formation of N-hydroxylated metabol ites (hydroxylamines). N-methylation 
of des imipramine has also been reported. 
Themetabol ic reactions of the imipramine series are catalyzed by 
enzymes or enzyme systems local ized in a variety of tissues and 
subcellular sites. Al iver microsomal multienzyme system catalyzing 
the sequence of oxidation and glucuronide conjugation is the centre "of 
the metabol ic activity for imipramine, as for most other drugs. 
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TABLE 4 
Scheme of the Major Pathways and Metabol ites of Imipramine 
I 1M NO H 
IDB ~-----IM ---•• DMI-----·DDMI 
I I 1 
20HIDB 
• 
20HIM - 20HDMI --20HDDMI 
I 
I 
I 
I 
I 11 Ii 
20H IDB-G 20HIM-G 20HDMI-G 20HDDMI- G 
The oxidative system responsible for the initial pathways of 
demethylation and aromatic hydroxylation is referred to as monoxygenase 
system; it involves the flavoprotein, NADPH cytochrome C-reductase, 
and cytochrome p-4so and oxygen. Imipramine forms a complex with 
cytochrome p-4so which results in a type I spectral change. The 
same has been observed with major unconj~gated metabolites. An 
in de pth study of this enzyme system will be covered in Section 5. 
Format ion of N-oxides from tertiary amines has been found to 
be independent of cytochrome P-450, but dependent on a flavoprotein 
amine oxidase, which is also local ized in hepatic microsomes. 
Considerable species differences in the metabol ism of imipramine 
and its metabol ites have been observed. Demethylation is the 
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predominant initial pathway in rats and guinea pigs whi le in pigs it 
is N-oxidation. Desimipramine rapidly undergoes further metabol ism 
in mice and rabbits but accumulates in rats and humans. The sex 
also has an influence on metabol ism of imipramine, but will be 
covered in Section 5. 
3.2. New Antidepressives 
Since the introduction of imipramine by Kuhn in 1957 for the 
treatment of depression, a number of new antidepressive drugs have been 
developed by altering the tricycl ic structure of the compound. 
However, it has been shown that drugs with different chemical structures 
and pharmacological and biochemical profiles also possess anti-
depressive properties. 
The following are the more commonly used newer antidepressives 
for the treatment of depression. 
3.3 Mianserin 
Mianserin,a new antidepressive, chemically a tetracycl ic 
piperazino-azepine (Fig. 2), was initially developed as an anti-
17 histamine and anti-serotonin compound • The pharmacological profile 
of actionofmianserin is different from that of the tricycl ic anti-
depressives. It combines presynaptic Cl a.drenoceptor blocking 
activity with anti histaminic properties, but has no central anti-
chol inergic activity and 1 ittle effect on central serotoninergic 
reuptake mechanisms. 
Mianserin 
Fig . 2 
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.3.3.1 Pharmacology 
3.3.1.1 Central Nervous System Effects 
The impairment of short term memory and learning capacity caused 
by amitriptyl ine but not by mianserin despite a tendency to a greater 
sedative effect with mianserin, suggests that mianserin lacks central 
anticholinergic effects 'S • Fatigue and drowsiness have been 
reported during administration of both mianserin and placebo, but the 
incidence was significantly higher in those receiving mianserin. 
Effect on sleep. Mianserin had no particular effect on healthy 
volunteers. However, mianserin improved sleep in depressed patients 
when compared with placebo. 
3.3. I .2 Action on Brain Amines 
In vitro or in vivo mianserin differs from the classical tricycl ic 
antidepressives in its capacity to reduce the concentration and 
inc rease the turnover of noradrenaline in the brain. 
Effect on Uptake of Noradrenaline 
Mianserin does not affect noradrenal ine uptake in vivo, and 
192021 increases its turnover' , . In vitro, inhibition of uptake has been 
reported n . In man therapeutic doses have no effect on peripheral 
noradrena ~ ine uptake, and unl ike the tricycl ic antidepressives do 
not significantly decrease the anti-hypertensive action of the 
23 h'd' 2. adrenergic neurone blocking drugs bellanidine ,or guanet line • 
Inhibit ion of serotonine rgic uptake mechanisms would thus not be expected in 
patients being treated with cl inical Iy effective doses of mianserin 22 
Effect on Serotoninergic Uptake Mechanisms 
I t ha s been repo rl ed t ha t m i a ns e r i n ha s e s 5 en t i a I I y no e ff ec t on ce n t r a I 
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serotonin uptake in v ivo in rats and is much less active than 
des imipramine or nortriptyl ine in inhibiting serotonin uptake by rat 
hypotha I m.i c synaptosomes 22 • 
In patients recovering from depression, whose blood platelets 
showed a significantly reduced capacity to accumul ate serotonin, 
mianserin produced a,n increase in serotonin transport to normal 
23 
va lues , although it had no effect on serotonin uptake into platelets 
in healthy volunteers. Mianserin did not affect serotonin uptake by 
rat blood platelets in vitro but it did induce release of serotonin 
f b ' 25 rom rat rain synaptosomes , 
3.3. 1. 3 Effect on Histamine Receptors 
A large number of structurally different antidepressive drugs 
inhibit histamine - sensitive adenylate cyclase and it has been 
suggested that this effect may contribute to the antidepressant action 
26 
of these compounds • Since mianserin is also a potent inhibitor, 
this may contribute to its mechanism of action. 
3.3. I .4 Cardiovascu lar Effects 
Findings of studies so far suggesL that mianserin is less liable 
to cause important adverse effects on the heart than the standard 
tricycl ic antidepressives 27,2B, 
3.3. I .5 Antichol inergic Effects 
29 The antichol inergic effects of mianserin in isolated organs on 
intact animals 3o , and in man 31 , are absent or clearly much less 
pronounced than those of amitriptyline. 
Dizziness, blurred vision, finger tremor and pronounced dry mouth 
occurred in a greater number of patients on amitriptyline than on 
. . 31 
mlanserln 
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The small antichol inergic effect may be attributed to a poor 
structure relationship with acetylchol ine as discussed in Section 2. 
3.3.2 Metabo Ii sm 
The predominant route of biotransformation of mianserin in the 
hu man is aromatic hydroxylation, N-oxidation, and N-demethylation 32 • 
Most of a dose is metabol ized, only 4 to 7% being present in the 
urine as unChanged drug. There are no publ ished data indicating 
whether or not the metabol ites are pharmacologically active. 
The mono-oxygenase system is respons i b I e for demethy I at i on and 
aromatic hydroxylation. 
3.4. Nomi fens ine 
Nomifensine is a tetrahydroisoquinol ine antidepressive (Fig 3), 
which is chemically distinct from the tricycl ic or tetracyclic 
antidepressives. monoamine oxidase inhibitors and other currently 
available agents. 
It differs from the tricycl ics in that it markedly inhibits the 
re-uptake of dopamine from presynaptic nerve terminals and has a 
relatively weak influence on the re-uptake of other catecholamines 
or serotonin. 
Nomifensine 
Fig. 3 
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3 . 4.1 Pharmacology 
3.4.1.1 Central Nervous System Effects 
Low doses reduce mobil ity and have sl ight sedative effect33 , but 
higher doses increase locomotor activity. The stereotype behaviour 
h · h d . d' . ff 3. seen at Ig er oses may In Icate presynaptic e ects • The 4 
hydroxyphenyl (M,) and 3 methoxy-4-hydroxyphenyl (M2) metabol ites 
produced stereotyped behaviour similar to that produced by nomifensine 3'. 
The s.tere"otyped behaviour is due at least in part to the dopaminergic 
properties of the drug. 
Effect on Sleep 
The M, metabol ite of nomifensine prolongs the hexobarbitone 
sleeping time when administered orally, whilst nomifensine itself 
significantly reduces the sleeping time . The M2 and M3 (3-hydroxy-
4-methoxyphenyl derivative) metabol ites have no consistent effects. 
Repeated doses of nomifensine 75 mg daily cause some deterioration in 
the abil ity to get to sleep, however, when compared to imipramine and 
placebo,some of the subjects feel more alert in the morning after 
receiving nomifensine 35 • On the other hand it was found that imipramine 
has a more beneficial effect on sleep disturbances in depressed out-
. 36 patients 
3.4.1 .2 Action on Brain Amines 
Nomifensine has been shown to strongly inhibit the uptake of 
noradrenal ine and dopamine in vitro into rat brain synaptosomes 37 , and 
to inhibit dopamine uptake i"nto human platelets in vitr0 38 • I n vi t ro 
nomifensine is a strong inhibitor of noradrenal ine and dopamine 
39 
uptake in rat brain and heart . The M, metabol ites are simi lar in 
potency to the parent compound in inhibiting dopamine uptake and 
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equipotent in inhibiting noradrenaline uptake . The H2 and H3 
metabol ites are les s active inhibitors of the uptake of biogenic 
amines, but are more potent than tricycl ic antidepressjves in 
inhibiting dopamine uptake in str iatal synaptosomes·o . 
Nomifensine is a relatively weak inhibitor of the serotonin 
uptake into various animal preparations in vitro'o , exhibiting 
activity comparable to mi anserin. Nomifensine has a moderate 
effect on serotonin uptake into human patelets in vitro. On the 
other hand, the HI metabol ite i s about 40 times more potent a 
compound in inhibiting serotonin uptake into rat brain synaptosomes, 
and has activity comparable with tha t of im iprami ne'o • 
Nomifensine does not affect the release of noradrenal ine and 
dopa mine from synaptosomes", and does not have direct stimulating 
effect on dopamine and noradrenal ine receptor sites . 
3.4.1.3 Cardiovascular Ef fects 
Studies on animals have shown that the effects of nomifensine 
are less pronounced th an those of imipramine, amitriptyl ine or 
d . d h . I d" 39 oxep I n un er t e same exper I menta con I t Ions • 
Findings of studies suggest that nomifensine is le ss liable to 
cause important adverse effects on the heart than the tricycl ic ant i· 
depressiveso Nomifensine has,as yet,not been associated with serious 
cardiotoxicity at therapeutic dosag e, and importantly on overdosage. 
3.4.1.4 Antichol i ner gic Activity 
At relatively high doses nomifensine inhibits contractions of 
isolated guinea pig intestine caused by chol inergic stimulation 39 • 
In man, nomifensine has less peripheral anticholinergic effect than 
amitriptyl ine as determined by measurement of sal ivary secretion 39 • 
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3. ~. 2 Metabo I ism 
Three principal metabol ites formed by hydroxylation and 
methoxylation of the phenyl ring are found in equal proportions 
(about 7%) inhuman serum and ur i ne·2 • Of these only the Ml 
metabolite is consistently active in vitro and in vivo. 
Following a single 25 mg dose, the amount of unchanged drug in 
serum is <5%, nomifensine being present mainly as the conjugate. The 
pathway can be seen in Figure ~ 
OH 
-
FIGURE ~ : METABOLISM OF NOMIFENSINE IN MAN 
Ml = ~ Hydroxyphenyl Nomifensine 
M2 = 3 Methoxy-~-hydroxyphenyl Nomifensine 
M3 3 Hydroxy-~-met hoxyphenyl Nomifensine 
OH 
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SECTION 4 
Drug - Receptor Interactions. Interaction of One or More 
Orugs with One Receptor System 
4. I . Dose Response Curves 
For an analysis of the action of drugs and of the relationship 
15 
between structure and action, dose response curves are indispensable . 
Theory 
When the effect of a drug is studied in a simple isolated organ 
suspended in a bath fluid such as Ringer or Tyrode solution, the 
influence of drug transference, transport, chemical trans f ormation, 
excretion, etc., is reduced to a mini mum. The concentration of the 
drug in the bio-phase in the isolated tissue preparation, may be 
supposed to be equal or proportional to that in the bath fluid, which 
may be supposed to be equal to the concentration or dose added. 
Receptors may be molecules, parts of molecules or molecule 
complexes. A single receptor can be occupied by only one molecule 
of the drug at a time. 
The formation of a drug-receptor complex may imply a very 
temporary interaction between drug molecule and receptor; it may be 
just a sl ight contact between the drug molecule and receptor. On 
the other hand, there may be a definite, possibly a prolonged, 
chemical binding between them. The bind i ng can be reversible or 
irreversible. Only reversible reactions will be discussed. 
The relation be~ween a drug, A, and the receptor, R, can be 
represented by: 
[R] + [A] ( 1 ) 
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Where [R] is the concentration of free receptors, [A] the drug 
concentration in the bio-phase, and [RA] the concentration of the 
drug receptor complex, that iS,the quantity of drug bound to the 
specific receptors. The total concentration of receptors, [r] is 
An increase of the concentration of the drug will 
result in an increase of the quantity of the drug-receptor complexes. 
Since the number of specific receptors in the biological object is 
limited, the maximal amount of drug-receptor complex has a 1 imit too. 
As long as a gradual increase of the dose of the drug results in 
a gradual saturation of the receptor system, the relation between the 
fraction of receptors occupied by the drug and the concentration of 
the drug in the bio-phase is assumed to obey the Mass Action Law, or 
the adsorption isotherm of Langmuir. 
In the case where the concentration of the drug is high compared 
to the number of specific receptors, it can be assumed to be constant. 
Then the fraction of the total number of receptors occupied by the 
drug A is represented by Equation 2. 
E 
I 
R f ~ f ] = 'I +""(T7:K""~"'1 "'[ A"T'j"'j (2) 
t 
A 
[RA]/[r] increaseswith the concentration of 
the drug, [A], nnd decreases with the dissociation constant KA of the 
drug receptor complex RA. Thus the 'affinity' of the drug for the 
receptor is proportional to the reciprocal of KA. E represents the 
effect . 
In order to induce an effect, a drug must interact with the 
receptor, that is, it must have an 'affinity' for the receptor. 
But this is not sufficient. It must interact with the receptors 
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in an 'effective' way; the drug must also have what is called an 
int rinsic activity. 
In the simplest although not the most probable case, the effect 
will be proportional to the quantity of drug-receptor complexes 
formed. The intrinsic activity of the drug is a measure of its ability 
to contribute to the stimulus and in this simp le case, to the effect. 
The stimulus is linearly proportional to the quantity of drug-receptor 
complex formed, but dependent on the intrinsic activity of the drug. 
A certain value of the stimulus always results in the same effect. 
A certain quantity of drug-receptor complex, however, does not 
necessa ri l y resul t in a constant stimulus . Here the intrinsic activity 
of the drug is determinant. The stimulus, SA ,expressed as a fraction 
of Sm, the maximal stimulus obtainable becomes 
(3) 
If a 1 inear proportionality between stimulus and effect is 
assumed, then the effect, EA ,induced in the effector, E, by a certain 
concentration of the drug, [A], as a fraction of the maximal effect, Em' 
obtainable with a drug of this type, is rep resented by equation 4. 
EA = 
Em 
[RA]a = 
[ r] (4) 
The effect obtained with a certain dose of A, that is the activity 
of A, increases with the intrinsic activity, a, and with the affinity 
1 
/KA· With high doses of A, the maximal effect for A, EAm is reached 
This gives us a mathematical equation for determi.ning the va l ues of 
the affinity and the intrinsic activity of a drug. The affinity is 
proportional to the reciprocal of that log concentration of the drug, 
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that g i ves a response equal to half the max imal response obtainable 
wi th that drug. The intrinsic activity of the drug that gives the 
hi ghest r esponse is taken as unity, then, relative values for the 
intrinsic activity of other drugs can be given. 
The dose response curves as calculated from equation ~ are 
hyperbo 1 i c. On a log dose scale they take the character of a 
sigmoicj curve. Figure 5 represents theoretical dose-response curves 
of various drugs calculated from equation ~. The' drugs used have 
varied affinity as well as intrinsic activity. 
Figure 5. 
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Theoretical log concentration response curves for 
compounds with varying va lues for the afinity (l/KA) 
and the intrinsic activity (Q). Note the parallel 
shift··in the curves with a variat ion in KA, and the 
decreases in the max i ma l heigh t and in the shape, 
with a decrease in u . 
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4.2. Competitive Interaction 
E 
I 
R 
/\ 
A B 
On the basis of the Mass Action Law, the effect, EAB' of the 
combination of the drugs A and B competing for the same receptor 
system, R, may be expressed as a fraction of the maximal effect, Em' 
as represented in equat ion 5. 
+ [RB]a 
[rj 
C! 
= 71 +"-""(I,..,+T[""B j""'/'""K;-B'"'J KO-A-'/T[ A""jr-
(5) 
+ 
The contribution of A and B to their common effect [AB] is 
determined by their concentrations [A] and [B], their affinity to the 
receptors or the reciprocals of the dissociation constants KA and KB 
of the drug-receptor complexes RA and RB, respectively, and by their 
intrinsic activities C! and 13. 
4.2.1. Competitive Antagonism 
Theory 
Suppose one of the drugs, B,has an intrinsic activity, 13 = 0 then 
the right term of equation 5 = O. 
Since competitive interaction exists at least two compounds must 
be involved. The easiest way to study the interactions of these 
compounds with respect to their biological effects is to make dose-
response curves of one of the compounds in the presence of constant 
concentration of the other. This means that two sets of curves are 
possible. 
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1. A set of dose response curves for compound A in the presence of 
compound B in a concentration which is constant for each curve 
but varies for the various curves. 
2. A set of dose response curves for compound B in the presence of 
compound A in a concentration which is constant for each curve 
but varies for the various curves. 
The activity of an antagonist against an agonist can be tested in 
two ways . 
1. 
2. 
The preventive one. In this case the antagonist is added first 
and prevents the effect of the agonist. 
The curative one. In this case the antagonist is added while 
the agonist e.g. a spasmogen, is in action. 
induced then is reduced by the antagonist. 
The contraction 
Most frequently one set of curves will be sufficient. Sometimes 
it will be useful to determine both as they may reveal different 
characteristics of the mode of action of the compounds. 
Figure 6 represents theoretical dose response curves calculated 
from equation 5. Here dose response curves for A, a compound wi th an 
intrinsic activity, a = 1, are calculated in the presence of constant 
concentration of 8, a compound with an intrinsic activity, B = 0, 8 
is a competitive antagonist of A. The presence of drug 8 results in 
a parallel shift of the log dose response curve for compound A to 
higher concentrations. The influence of 8 can be overcome by an 
increase in the dose of A. An increase in the dose of A always 
results finally in occupation of all receptors by this compound. 
The more of 8 that is present, the higher must be the dose of A in 
order to obtain an effect equal to EAm. 
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Figure6. The theoretical concentration response curve for an 
agonistic compound A combined v/ith vdrious concentrations 
of a competitive antagonist B. (Equation 5 . KA = Ks = I, 
a = 1$ = 0). Note the paral lei shift in the curves for 
A. Concentration in H- 1 • 
4.2.2. Evaluation of Agonists and Competitive Antagonists 
The dose of an agonist, A, which produces an effect, EA.that is 
50% of the maximal effect, EAm, that can be produced by the agonist. 
is called the E050' According to the theory:-
KA [A] if EAm = 2 
EA 
Hi Iler introduced the so-called pO values, the negative 
logarithms of the concentrations concerned in moles/I itres. Ariens 
used the nomenclature pOx, where x is equal to EAm/EA. The E050 
gives the pOZ as an experimental value, which correlates with 
-log KA from the theory, and therefore with the affinity of A for 
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the receptors. 
Since KA = [A] it can be said that these values equal 
dissociation constants. Dissociation constants are expressed as a 
positive value, i.e. 
pD2 - log concn = log KA 
The higher the pDZ value, the greater is the affinity of the 
drug. 
Competitive antagonists are better approached on the basis of 
the pAx values. In the case of competitive antagonism, the dose 
response curves for the agonist are shifted in a paral lei fashion 
by the antagonist. 
The negative logarithm of that dose of the antagonist that 
requires a doubl ing of the dose of the agonist to compensate for 
the action of the antagonist, is called the pAZ value. If instead 
of a double dose, a tenfold dose of the agonist is needed, it is 
called the pAlO value etc. It fol lows from equation 5 that the pAZ 
value is proportional to the negative logarithm of KB' 
Since KB = [B] 
pAZ =-Iog [B] 
pAZ is therefore determined when [B] is such that a doubl ing 
of agonist is required to compensate for the action of antagonist B. 
4.3. Non competitive Interaction 
E 
I 
R - R' 
t t 
A B 
B interacts with receptorsR',which are different from those for 
A, then the relation between A and B is a non-competitive one. 
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The contribution of drug A to the effect is changed by B. The 
occupation of the receptor s R' by B as such, does not result in any 
effect. Only if A is present, can B change the response obtained 
wi th A. The degree to which this happens depends on the degree to 
which the receptors R' are occupied by B. This relationship is 
expressed in equation 6. 
[ 
S' 1 
1 + {K'B[B]+Jj (6) 
B' is the intrinsic activity of B with respect to the change induced 
in the effect of A. The occupation of R' by B results in a virtua l 
change in the intrinsic activity of A. K'B is the dissociation 
constant of the drug-receptor complex R'B. The interference of B 
can result in an increase or a decrease of the response of the 
effector system. Then B' has to be suppl ied with a positive or 
negative sign respectively. 
Theory 
Depend ing on t he value of the intrins ic activity 8', the 
antagon i sm may be comp 1 ete or pa rt i a 1. If -1 is subs t i tuted for 8 ' 
for high doses of B. EAB/Em becomes zero. Hence there is complete 
antagonism. Figure7 represents the theoretical dose-response 
curves calculated from equation 6, by substituting -1 for 6'. In 
the case of competitive antagonism the effect is determined by the 
relation between the concentration of agonist and antagonist; the 
antagonism is surmountable. 
In the case of a non-competitive antagonism the effect is 
determined by the concentration of the antagonist only. There is no 
shift in the curves but a gradual decl ine and disappearance of the 
effect at high concentrations of B. The non-competitive antagonistic 
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action is surmountable; this is true if high doses of the agonist 
or high doses of the antagonist are used. If lowe r doses of both 
the agonist and antagonist are involved, the decrease in the effect 
cau sed by the antagonist may be abol ished to a certain degree by an 
increase of the dose of the agonist. In that case,the non-competitive 
antagonist is surmo untable to a certain degree . 
If a value between a-I ,say a,S, is substituted for intrinsic 
activity 8', with high doses of B the second term of equation 6 
becomes a,S and the effect of A is reduced by 50% of its original value. 
Then there is a partial non -competitive antagoni sm . 
E,.~I[m 
co E [e) 0 
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,. Jt - A 
'" I I 
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Q, 
8 I ~
,e 
Figure 7 . Theoretical log concentration-response curves for the 
agonist A combined with various concentrations of the 
non-competitive antagonist B. (Equation 6 KA = KB' = l,a = I. 
S ' =-1) Concentration in H- 1 
4.3 . 1. Evaluation of Non-competitive antaqonists 
Fo r non-competitive antagonists a procedure analogous to that 
used fo r an agonist may be followed. In the case of the agonist, 
pOx values are used. The pOZ value corresponds to the negative 
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logarithm of that dose of the drug for which EAm/EA reaches a value 
of 2. From equation 6 it fol lows that if the effect EA of an 
agonist A is reduced by a non-competitive antagonist B, of which 
the intrinsic activity 8' is = -I, to 50% of its original value, 
and if EA/EAB' = x = 2, [B] is equal to KB. This 
impl ies that the pO'2 value which is - log [B] for x = 2, becomes 
equal then to - log K'B. A criterion fo r the non-competitive 
inhibition, is that the pO'x value of antagonist is independent of 
the original effect EA' 
Theories for the possible mechanism by which tricyclic 
antidepressives act as antagonists have now been discussed above. 
For further theories on other competi~ive antagonisms, the reader 
i s referred to Ariens 15 . 
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SECTION 5 
THE EFFECTS OF DRUGS AND STEROID HORMONES ON 
THE ENZYMES OF THE ENDOPLASMIC RETICULUM 
5.1 Drug Metabolism Concepts 
The hepatic drug metabol izing enzymes are membrane bound and are 
located in the microsomal membranes of mammal ian I iver cells. These 
membranes are derived from the rough and smooth endoplasmic reticulum. 
These enzymes are invol ved in the oxidative metabol ism of drugs, steroids 
and other hormones with biosynthesis of cholesteral 43 .44, and its 
b I · b'l 'd 45, 46 h 'd' f f 'd 47,48 d cata 0 Ism to I e aCI s , t e OXI atlon 0 atty aCI s an 
the oxidation ~f prostag l andins 4'. 
The enzymes of the hepatic endoplasmic reticulum, which metabol ize 
drugs and steroids are often referred to as the m.icrosomal drug 
metabol izing enzymes, and are responsible for the oxidation, reduction 
and conjugation of drugs,other foreign compounds (xenobiotics) such as 
pesticides, food additives and industrial chemicals, 
The hepatic drug metabol izing enzymes function as a multicomponent 
e l ectron transport system5~51~he microsomal electron transfer reaction 
(Figure 8) reveals the function of at least three flavoproteins, two 
hemoprote i ns and iron conta i n i ng prote in. 
The flavoproteins functionas reduced pyridine nucleotide 
dehydrogenases and they participate in the transfer of reducing 
equivalent to cytochrome bs from NADH, via the flavoprotein (fp,), 
NADH-cytochrome b s reductase, or from NADPH by flavoprotein (fp z). 
52 NADPH cytochrome P-450 reductase . The reduced flavoprotein, fp z 
53 
can also undergo oxidation by ferric cytochrome P-450 , to react with 
molecular oxygen giving rise to a superoxide anion for the initiation 
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of lipid peroxidation or heme degradation. A third flavoprotein 
(fp3), participates in the oxidation of tertiary amines giving rise 
to N-oxides 54 • This fp3 may also function in an oxygen dependent 
oxidation of sulfhydryl groups for the formation of disulfide bonds . 
5. I. I Proposed Cycl ic Function of Cytochrome P-450 
One postulated scheme illustrating the cycl ic pattern of 
reduction and oxygenation of cytochrome P-450, as it interacts with 
substrate molecule, electron donors and oxygen is shown in Fig. 9. 
Briefly, the reaction may be summarized as fol lows: 
(a) The ferric hemoprotein (Fe+ 3) can interact with a mo lecule of 
substrate (R) resulting in a complex (Fe+ 3R). The orientation of 
the substrate molecule as it sits in proximity of the heme iron, 
the presumed binding site for oxygen, remains a conjecture although 
the role of steering groups on the substrate molecule or the influence 
of hydrophobic environment of the heme may be considered as possible 
directing forces. 
(b) The substrate complex ferric-cytochrome P-450 (Fe+ 3R) undergoes 
reduction to a fe r rous cytochrome p-450 substrate complex (Fe+2R) 
by electrons originating from NADPH and transferred by the flavoprotein 
(fP2) NADPH-cytochrome P-450 reductase. 
(c) Reduced cytochrome p-450 (Fe+2R) can react with carbon monoxide to 
form a derivative which is readily identifiable spectrophotometrical Iy 
by an absorbance band maximum at about 450 nm. Alternatively, reduced 
cytochrome P-450 can react with oxygen to form a complex termed 
oxycytochrome p-450 (Fe+202-R). 
(d) Oxycytochrome P-450 (Fe+202-R) can presumably dissociate to give 
a superoxide anion (02) concomitant with the regeneration of the ferric 
hemoprotein. Alternatively, the complex of oxycytochrome p-450 may 
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Figure 8_ Schematic Diagram of Microsomal Electron Transport Reactions 
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undergo further reduction to form the equivalent peroxide anion 
derivative of the substrate bound hemoprotein . Studies with the 
membrane bound cytochrome p-450 of liver microsomes suggest that a 
donation of a proposed second electron occurs via cytochrome b s . 
This conclusion is the basis for explaining the syner9 ~istic effect 
observed during the concomitant oxidation of NADPH and NADH by 
this system. 
(e) The proposed peroxide anion complex of cytochrome p-450 may 
undergo protonation and dissociate as hydrogen peroxide or it may 
rearrange to form anoxime derivative concomitant with the release 
of water. 
(f) Least understood is the mechanism of dissociation of the 
hydroxylated product and the restoration of the low spin form of 
ferric cytochrome P-450. 
5. 1.2 Drug Hydroxylations 
It has been suggested that one single enzyme system is responsible 
for all the differing types of hepatic microsomal hydroxylations which 
51 
may include the following 
Al iphatic oxygenation 
Alicycl ic oxygenation 
Aromat ic oxygenation 
Epoxidation 
o and N-dealkylation 
, 
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Furthermore, it is considered that this one enzyme system is 
responsible for the oxygenation of all the different substrates, 
including drugs and other foreign chemicals, steroids and fatty 
acids. 
5. I .3 Cytochrome P-450 and Spectral Changes 
To obtain an indication of the type of bonding between 
xenobiotic and cytochrome P-450 during drug metabol ism by the 
mixed function oxidase system, spectroscopic studies can be appl ied. 
5.1.3. I Carbon monoxide Difference Spectrum 
A difference spectrum is generated whenamicrosoma l fraction is 
divided into two identical cuvettes, then placed in a dual beam 
spectrophotometer and a basel ine run between 500 nm and 360 nm. A 
compound (in this case carbon monoxide) is added to the sample cuvette 
and the resulting spectrum measures the'difference between the 
refe rence and sample cu ve ttes (see FigurelO). 
The absorpt ion spe ctrum of the reduced (Fe 2 ;) form ,,,hen bound to 
b 'd' , I h f 450 nm 52 . 53 car on mo noxi e gives a ma ximum at a wave engt 0 
A smaller peak at 420 nm also exists because some P-450 is 
54 
converted to a new complex wi th a maximum absor pt ion at 420 nm , 
Carbon monoxide competitively inhibits the enzyme since it 
competes with oxygen for the binding sites on reduced (Fe 2 +) 
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sytochrome p-450. Moreover, this inhibition is reversible with 
55 irradation with I ight at wavelength of 450 nm • 
450 
FIGURE 10 . CARBON MONOXIDE DIFFERENCE SPECTRUM 
,\/nm 
5. I .3.2 Spectral Changes and Binding of Cytochrome P-450 t o Drugs 
The binding of many compounds to the microsomal mixed function 
oxidase system produces two distinct type of difference spectra. 
These spectra are termed type I and type: . 11 spectra. Compounds 
giving rise to type 1 and type II difference spectra with hepatic 
mi crosomes have come to be known as type I and type II compounds. A 
third, less common spectrum, a reverse type I, is also possible. The 
various types of spectra are depicted in Figure 11. 
The binding of substrate to microsomal cytochrome probably 
precedes enzymatic oxidation, and the ma nifestation of a spectral 
change is regarded as evidence that an enzyme compound complex is 
formed. The type I spectrum has a max imum at 390 nm and a mini mum at 
420 nm (Fig. lla). Compounds wh ich give rise to t ype include :-
imipramine, testosterone, barbiturates,aminopyrine. The type I I 
spectrum is characterized by a peak at approximately 425-435 nm and 
a trough at 390 nm (Fig.llb). 
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FIGURE 11 . DIFFERENCE SPECTRA 
Type II substrates normally contain a basic nitrogen atom and 
include compounds such as anil ine, pyridine and 2,4-dichloro-6 
phenylphenoxyethylamine hydrochloride. These compounds are 
generally not metabol ized by cytochrome P-450. Ev idence has 
shown that ma ny compounds ma y combine in varying degrees with both 
binding sites and this may explain the metabol ism observed with 
56,57 
some type I I compounds 
A/nm 
The reverse type I (RI) spectrum (also known as mod ified type II) 
has a peak at 420 nm and a trough at 392 nm (Fig. llc). The cause of 
this spectrum has been explained and one explanation is that compounds 
(methanol, ethanol, I-butanol, acetone and phenacetin) which elicit 
such a spectrum do so by displacing endogenous substrates from 
cytochrome P-450 58 , i.e., the RI spectral change is caused by 
reversal of structural state of p-450 caused by prior binding of 
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.endogenous substrate to the enzyme in vivo. 
Some reverse type 1 substrates are metabol ized. One proposed 
metabolism is that they are bound first to the type 1 site, then 
with increasing concentration to another site as wei I, giving rise 
h · h b h 1 57, 59 to a new spectrum w IC 0 scures t e type component 
Binding of a type 1 compo und is thou gh t to change the conformation 
of the protein, so that the Fe-binding shifts from the sulphur of one 
amino acid of protein to a nitrogen of a nearby amino acid. This 
shift from sulphur to nitrogen might cause the type 1 difference 
spectrum. Type 11 compounds are thought to bind as 1 igands to the 6 
position, which is the site for oxygen i.e., ferric haemochrome 
formation. 
Binding of type 1 and type 11 compounds may occur as depicted 
in Figure 12, 
5.2 The Biological Function of the Hepatic Microsoma l Drug 
Metabolising Enzymes 
Drug metabol ism occurS ·in two phases. Phase 1 is commonly an 
oxidation, a reduction or hydrolysis. ~hase 11 is always a 
conjugation reaction. The purpose of drug metabol ism is to convert 
the compound into a form which is more water soluble. The easiest 
way of achieving this is by conjugation with for example, glucuronic 
acid in a phase 11 reaction. But for conjugation to occur there 
mus t be a group in the molec ule which ca n react with the conjugating 
a gent. In general', this mea ns t ,hat an ionic group is neede d. Many 
drug molecules possess no such group and the purpose of a phase I 
reaction is to introduce such a group. 
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The low Michael is constant which characterizes the 
hydroxylation of testosterone, progesterone and oestrad io l by 
hepatic microsomal enzymes supports the concept that the endogenous 
steroids are the normal physiological substrates and indeed 
preferential substrates of the oxidative drug metabol ising enzymes 60 • 
5.3 The Effect of Drugs and Foreign Compounds on the Hepatic Drug-
Metabol ising Enzymes 
The increased activities of the hepatic microsomal drug 
metabol ising enzymes following the treat ment of animals with a wide 
variety of drugs, pesticides, food additives, polycycl ic hydrocarbons 
and other foreign compounds is now extremely documented. Stimulation 
of these enzymes occurs only when the inducing compounds are 
administered to the living animal or are perfused through isolated I iver~1 
and addition to preparation of the microsomal enzymes in vitro produces 
no stimulatory effect. 
The drugs and foreign compounds which produce stimulation of these 
enzymes have widely differing pharmacological activities,and the only 
factors which they would all seem to have in common,are that they are 
I ipid soluble and hence become localized in the endoplasmic reticulum 
of the I iver, and are substrates of the microsoma l mixed-function 
oxygenase. 
5.3. I Mechanisms of Induction of Hepatic Drug Metabol ising Enzymes 
by Drugs and Polycycl ic Hydrocarbons. 
The first enzyme that increases during induction is S-amino 
levul inic acid synthetase, which is in vo l ved in the synthesis of 
heme 51 This is followed by cytochrome P-450 and the specific 
flavin enzyme for electron transport. AI I the other enzymes not 
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involved in drug hydroxylation increase later on to a much smaller 
extent • This is the case for cytochrome b5 and the relevent 
. f' 62 unspeci Ie esterase . 
If treatment with an inducing agent is not terminated the 
increase in cytochrome P-450 continues until a maximal amount is . 
formed after three to five days, and a new steady state is 
achieved. So long as the inducing agent is present in the 1 iver 
cel Is it enhances the rate of synthesis of the heme as well as of 
the protein moiety by causing an increase in messenger RNA 
formation in the 63 nucleus . 
Induction of induced enzymes is completely prevented if either 
actinomycin D, which acts at the level of transcription, or 
cycloheximide or puromycin,which act at the translation level, are 
concomitantly administered with inducing agent. Gerlehrter (1973) 6. 
mentions that stimulation of enzyme actively becomes insensitive to 
actinomycin D during treatment with inducer,and Nebert and Gilboin 
65 (1970) found that the inducing system became insensitive to 
actinomycin D, but continued to be cycloheximide sensitive, i.e., 
protein synthesis is required continuously. These two processes for 
induction appear necessary:-
(a) Synthesis of induction specific RNA which is cycloheximide 
insensitive and thus translation independent. 
(b) Translation related to the induction specific RNA which is 
insensitive to inhibition by actinomycin D and thus transcription 
independent. 
The induction specific RNA may accumulate at the nuclear site 
bound to DNA. This accumulation of RNA causes the induction process 
to pass from the transcription-dependent to the transcription-
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independent stage. The second, the translational step, involves 
the synthesis of either enzymes, protein, or a rapidly synthesized 
and degraded protein activator of the enzyme complex. 
A significant enhancement of drug metabol izing enzymes is 
visible with an, electron microscope. The smooth (but not the rough) 
membranes in the I iver cells increase considerably. With the growth 
of the endoplasmic reticulum the I iver becomes larger, predominantly 
by hypertrophy. This does not mean that any enlargement of the 
endoplasmic reticulum is necessarily associated with an increase in 
drug metabol izing enzymes. The magnitude of induction is also 
highly dependent on the age of the animals. One tenth of the 
phenobarbital dose in weaning rats produces nearly the same 
induction as the full dose in adult animals 66 
Observations during therapy and cl inical studies show that an 
increase in drug metabol ism can occur in man also 67 • Howeve r, 
the number of drugs known so far to act as inducers of the 
hydroxylating system during therapy is small; these include 
barbiturates, glutethimide, meprobamate, phenylbutazone, phenytoin 
and the antifungal agent griseofulvin. This 1 ist is far from complete. 
The inducing action of these drugs in man, however, is exceedingly 
inconsistent and many patients treated with the same compound at the 
same dose levels did not respond with increased drug metabol ism 68 • 
5.3.2 Conditions Necessary for Induction 
(I) The majority of 1 ipid soluble compounds metabol ized by the 
microsomal oxygenase have some inducing properties. This is true 
even for ethanol and for those drugs such as barbital which cannot 
be hydroxylated in measurable quantities during the period of 
testing. Alkaloids, however, seem to have no inducing capacity. 
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(2) The inducing action is dose dependent . However, many drugs 
are active only at nearly toxic doses; a few, however, such as 
long-acting barbiturates can induce the enzyme system when therapeutic 
doses are taken. 
(3) Most important is the main tenance of a high concentration in 
I iver cells for a certain time. 
5.4 The Metabol ism of Steroids by the Endoplasmic Reticulum 
Many tissues other than the liver, for exa mp I e the ad rena I cortex, 
the testicular interstitial tissues, the corpus I-Dteum, and the placenta, 
wh ich are concerned with the biogenl~ j s of the steroid hormones, have 
been shown to contain well developed endoplasmic reticula and microsoma l 
enzymes, which are involved in metabolic pathways of cholesterol and 
steroid hormones. 
The endoplasmic reticulum of the I iver contains a number of enzymes 
which further metabol ize and deactivate the steroid hormones, as these 
include the 213, 6a, 613, 7a, 16a hydroxylases and the 4,5M 4 oxidoreductases 
69,70 These enzymes probably catalyse the first step of the conversion 
and have been shown to require NADPH2 and oxygen and to be inhibited by 
45 46 
carbon monoxide and an ant i body to NADPH cytochrome-C-reductase •. 
5.4. I Metabol ism of Oestrogens 
The metabol ism of oestrogens is outl ined in Figure13. Oestrone 
and oestradiol are interconvertible by a 1713-hydroxysteroid dehydrogenase. 
The conversion of oestradiol to oestrone appears to be mo re rapid than 
the reduction of oestrone t o oestrad iol and oestrone probably serves as 
the precursor of hydroxylated metabol ites rather than oestradiol. One 
of the main metabol ic pathways for oes trone appears to be hydroxylation 
to 16a- hyd roxyoes t rone fo II owed by reduc t i on to oes t rio I . Some of the 
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oestriol produced is oxidized to 16-oxooestradiol and thi s can 
undergo reduction to 16g-hydroxyoestradiol (16-epioestri ol) . 
Some 16a -hydroxyoestrone ca n be reduced by the enzyme 17a -
hydroxy steroid dehydrogenase with the formation of 17-epioestriol 
but this does not appear to be quantitatively significant. The 
second important pathway appears to be by hydroxylation at position 2 
with the formation of the catechol 2-hydroxyoestrone. The 2-
hydroxy compounds are readily converted to 2- methoxy oestrogens by 
an a-methyl transferase. Demethylation of the 2-methoxyoestrogens 
occurs to only a 51 ight extent. The 6a-and 6B-hydroxy lases result 
in the for mation of 6a- and 6S-hydroxyoestrone and 6a- and 6S-
hydroxyoestradiol. 
After administration of ["e] oestrone or oestradiol,between 
50% and 80% of the radioactivity is excreted in the urine within 
four to six days and up to 18% may be found in the faeces. Since 
the faecal excretion is much smaller, a large amount of t he 
metabol ites excreted in the bi Ie, is reabsorbed and enterohepatic 
circulation of oestrogens occurs. The metabol ites in the urine 
appear to be excreted ma inly as glucuronides although sulphates 
exist 71. Except in a few instances unconjugated metabol ites occur 
in very small amounts. About 20% of the· radioactivity in the 
extracted urine consists of oestrone, a bout 20% oestriol and a 
further 20% consists of 2-hydroxyoestrone. Smaller amounts 
(about 5%)of 2-methoxyoes trone are also present. 
5.4.2 Metabol ism of Progeste rone 
The major metobol ic pathways undergone by progest ero ne are 
shown in Figure 14 The action of the 4-ene-reductase l eads to 
the production of Sa-and 5B'pregnanediones which are then reduced by 
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the 3a-hydroxy and 3S-hydroxy steroid dehydrogenases. The former 
is much more active than the latter so that 3a-hydroxy steroids are 
formed predominantly. A number of tissues contain 20a-hydroxy 
and 20S-hydroxy steroid dehydrogenases of which the former is much 
mo re acti ve in humans. As a result of these enzymes the C-20 
oxo group is reduced to hydroxy; these en zymes appear to util ize 
either progesterone or the pregnanolone as substrates. By the 
action of the reductases and dehydrogenases eight possible isomer s 
of pregnanediol can be produced but only three of these are of any 
importance. 5S-Pregnane-3a ,-20a-dio l is by far the most impo rtant 
single metabol ite of progesterone. About 5% of administered 
progesterone is excreted in the form of pregnanolones and up to 
2% as pregnanediones. Hydroxylation reactions are more important 
in the metabol ism of progesterone than in the metabol ism of androgens 
and up to 7% of the dose may be converted to metabol ites containing 
a 6a-hydroxy group while possibly another 5% is converted to 
71 
metabolites containing a 16a-hydroxy group Progesterone itself 
does not appear in urine except for very smal I amounts detected in 
late pregnancy. After the administration of [ 14 cJ progesterone between 
50% and 60% of the dose is excreted in urine; up to about 10% may be 
excreted in the faeces. Since about 30% is excreted vi a the bile it is 
evident that considerable reabsorption mus t occur. 
5.4 . 3 Metabol ism of Androgens 
Since testosterone and androstenedione are interconvertible the 
meta bol ism of these two compounds is considered together. The main 
me tabol ic pathways are shown in Figure 15 • The 17-oxo steroids and 
17S-hydroxy steroids are interconvertible by the enzyme 17S-hydroxy 
steroid dehydrogenase; although the 17-hydroxy steroids have a greater 
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bLDlogical activity than the 17-oxo steroids, the 17-oxo steroids 
predominate in urine. The first stage in metabol ism is reduction 
of the double bond in ring A carried out by the 4-ene-5a and 4-ene-
58 reductases, which seem to have some substrate specificity. 
Reduction of this double bond with the production of 5a- and 56-
androstenedione leads to a marked reduction in the biological 
activity of the steroid. 178-Hydroxy-5a-androstan-3-one (5a-
dihydrotestosterone) is important since this compound has considerable 
biological activity and seems to be produced from testosterone in 
" target organs from the male sex hormones . A number of tissues 
contain both 3a-hydroxy and 38-hydroxy steroid dehydrogenases; the 
activity of the former seems to predominate and more 3a- than 38-
hydroxy steroids are formed. After administration of label led 
testosterone or androstenedione the greater part of the urinary 
radioactivity was associated with 5a-androstanolone (androsterone) 
and 58-androstanolone (etiocholanolone). The percentage conversi o n 
of androstenedione or testosterone to urinary metabol ites was 
approximately .as fol lows: androsterone, 20%; etiocholanolone, 26%; 
36-hydroxy-5a-androstan-17-one, 1%; 5a-androstanediol, 1% and 55-
androstanediol, 1,5%. 6-Hydroxy and 19-hydroxy derivatives of 
testosterone and androstenedione are known although under most 
circumstances pathways leading to these compounds are minor ones. 
Smal I amounts of 17a-hydroxy-androst-4-en-3-one (epitestosterone) 
are produced, presumably from androstenedione by the action of a 
17a-hydroxy steroid dehydrogenase. In addition to glucuronide 
conjugates, sulphate conjugates are also known in the case of C-19 
steroids and most of the 38-hydroxy-5a- and 58-steroids are 
predominantly conjugated with sulphuric acid. The 3a -hydroxy 
HO 
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steroids appear mainly as the glucuronides al though son:e sulphate 
formation takes place. 
After administration of [ I' C] testosterone, abou t 90% of the 
dose is excreted in urine, and about 6% appears in faeces. Since 
about 14~ of the dose is excreted in the bile some reabsorption of 
the steroids from the gastro-irtestinal tract must take place . 
5.4.4 Hetabol ism of Synthetic Oestrogens 
Only ethi oyl oestradiol will be discussed here, the reader is 
71 
referred to reference for further information on mestranol, 
quinestral, and 17a -methyl oestrad io l. 
The ..!..!2. vivo me tabol ism of 17a-ethinyl oestradiol in man has 
been thoroughly investigated; it was found thattheeli minati onrateand 
the type of conjugation was approximately the same as for natural 
72 
oestrogens It was found that in man 17a-ethinyl oes tradiol 
reacts to form numerous metabol ic products, the mos t important of 
which are 2- methoxy-17a-ethinyl oestradiol, 2-hydroxy -17a-e th inyl 
oestradiol-3- methyl ether, and 0 homoestradiol-17S (Fig.16). 
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5.5 The Ef fects of Steroids on Hepatic Drug Metabol ism 
Steroids of all kinds, the endogenous corticosteroids, 
androgens, oestrogens and progestogens and various synthetic 
steroids have been shown to affect the metabolism of drugs by 
altering the act ivity of the drug metabo l izing enzymes of the 
I . 67 Iver • Table 5 shows the similarities between the hepatic 
microsomal enzymes which hydroxylate drugs and steroids 73 • 
TABLE 5 SIMILARITIES BETWEEN HEPATIC HYDROXYLASES THAT METABOLIZE 
STEROIDS AND DRUGS 
(I) Localized in livermicrosomes; require NADPH and oxygen for 
activity. 
(2) Activity is higher in male than female rats, with I ittle or 
no difference in mice. 
(3) Activity is higher in mamma l ian I iver but 100,er in fish liver. 
(4) Activity is increased by pretreatment with drugs, pesticides 
and steroids. 
(5) Activity is inhibited by in vitro addition of SKF 525-A o r 
Chlorthion 
(6) Drugs and steroids exhibit competitive inhibition with each 
other in vitro. 
(71 Activity shows a diurnal variation with minima l drug 
me tabol izing activity coincident with maximum plasma levels 
of corticosteroid. 
Since drugs and steroids would appear to be alternative 
substrates fo r the same hepatic microsomal mixed function oxygenase 
system, theymight be expected to exh ibit competitive inhibition of 
the enzyme system in vitro, and within a short period after 
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administration ~ vivo, though after a longer interval should give 
rise to an increase in the enzyme activity. 
It has long been known in the rat that the duration and 
intensity of drug action is greater in the adult female than in the 
male. This difference of activity is due to an enhanced level 
of the hepatic microsomal drug metabol izing enzymes in the adult male 
rat and must be produced by the male sex-hormones for it only appears 
at puberty and may be abol ished by castration 73 • This sex 
difference has not been observed to the same extent in other animals. 
Testosterone administered to female rats increases the rate of 
metabol ism of many drugs and conversely the opposite effect is 
produced by the administration of oestrogens to the male animal 67 • 
Mice behave somewhat differently, a single dose of testosterone to 
female mice producing a biphasic effect, initially prolonging the 
action of hexobarbital and after a few days reducing this. Long 
term pretreatment of female mice with testosterone reduces the 
pharmacological activities of hexobarbital and chlorzoxazone by 
increasing their metabol ism 7'. 
Cortisol, progesterone, testosterone, androsterone and 
oestradiol-17S all competitively inhibit the ~ vitro hydroxylation 
of hexobarbital and the N-demethylation of ethinyl morphine by rat 
I iver microsomes, consistent with the view that steroids and drugs 
are alternative substrates for the hepatic microsomal mixed-function 
75 
oxygenase system . 
5.6 The Effect of Pregnancy on the Metabol ismof Drugs 
There has been a growing opinion among cl inicians that pregnancy 
in humans imposes an inhibition on the abil ity to metabol ise and 
d . d 76 eactlvate rugs . During pregnancy there is a considerable 
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increase in the formational circulation of the female sex steroid 
hormones, both progestogens and oestrogens, and since these 
steroid hormones may be metabol ized by the same hepatic microsomal 
enzymes which metabol ize drugs, it is possible that they may 
competitively inhibit the metabol ism of drugs. 
It has been shown that in pregnant rats and rabbits,and in animals 
pretreated with progesterone, the glucuronide conjugation of a 
number of substrates was markedly inhibited 77 • Sulphate 
conjugation is also inhibited during pregnancy and it has been 
7B 
suggested that this is due to the high levels of oestrog en . 
5.7 The Effect of Oral Contraceptive Steroids 
Since endogenous steroid hormones may act as competitively 
inhibiting substrates for the hepatic drug-metabol izing enzymes, and 
both natural oestrogens and progestogens of pregnancy have been shown 
to be associated with inhibition of these enzymes, it may follow 
that oral contraceptive steroids could also have an inhibitory effect 
which, in view of the extensive and prolonged usage of these compounds, 
might be highly undesirable. It has been shown that one hour after 
administration of norethynodrel to rats the ~ vitro met abol ism of 
both hexobarbitone (a type I substrate) and of zoxazalamine (a type 
II substrate) was inhibited, whereas 24 hours later the metabol ism 
f b h d . d 7B o ot compoun 5 was Increase . The oestrogen mest ranol administered 
to mice daily for 4 days inhibited the metabol ism of hexobarbital and 
pentobarbital and increased the sleeping times produced by these 
barbiturates; on the other hand Lynestrenol, a progestogen simi larly 
d .. d h d h b I' f h b b . 79 , BO d a ml n I stere ,en ance t e meta a Ism 0 t ese ar I turates an 
also that of ~henytoinBo. With acute treatment (2 hours after 
dosage) norethynodrel andethinyl oestradiol inhibited the ~ vivo 
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met abol ism of pentobarbital in rats. Whereas after chronic 
treatment (30 days) this ~~metabolism was significantly 
. d 81 Increase . 
In summary it would appear that many of these contraceptive 
steroids are acceptable substrates for the hepatic microsomal 
drug metabol izing enzymes,giving rise to modest inhibition of drug 
metabol ism in vitro,and variable extents of induction of the 
various microsomal drug me tabol izing enzyme activities in vivo 
---, 
which on prolonged treatment finally return to approximately 
no rma I I eve Is. The long term use of these oral contraceptive 
steroids thus appears unl ikely to result in any major changes in 
the levels of the hepatic drug metabol izing enzymes, and hence is 
unl ikely to result in any marked changes in the activity of drugs . 
5.B Sex Hormonal Alteration of Imiprami ne Response 
5.8.1 Imipramine-Ethinyl Oestradiol in Women 
Depression is more common in women than in men. It appears 
that men respond more promptly than women to imipramine. Some 
androgens could not be given to wome n because of mascul inization, 
so as to enhance imipramine response, the idea of oestrogen 
administration was considered. Oestrogen was used, as oestrogens 
appear capable of producing mood changes of either s ig n in some 
82 
wome n ,therefore, although oestradiol was administered to thiry 
depressed women, so as to enhance the antidepressant activity of 
.. . P A - 183 Imipramine, range .J.~~ . reported that five depressed 
patients on daily doses of 150 mg imipramine and 50 ~g ethinyl 
oestradiol did not improve as much as ten women who recei ved 
imipramine and a placebo after the first week of the drug trial. 
Also, the patients showed signs of toxicity. Four of the five 
-68-
complained of severe lethargy and four of severe hypotension. Two 
had a coarse tremor and five showed signs of mild depersonal ization. 
The mechanism of imipramine -oestrogen interaction is unclear. 
Oestrogen may inhibit the N-oxidation and demethylation of imipram ine 
causing accumulation of imipramine in the brain and other tissues, 
but this theory has not been critically evaluated. Other steroids 
such as norethindrone (a progesterone derivative) produced similar 
effects with imipramine in mice 8 •. It has also been shown that 
ethinyl oestradiol inhibited the metabol ism of ethyl morphine and 
hexobarbital . 75 In rats. 
5.8 . 2 Imipramine - Methyl Testosterone in Men 
Prange and coworkers 85 reasoned that if being 'more female' 
worsens the patient's response to imipramine (if only in the realms 
of toxicity), and if being male improves it as we I I as reducing the 
risk for depression, then being 'more male' might further improve the 
response to imipramine. 
Five men were treated with 15 mg met hyl testosterone and 50 mg 
imipramine. Four of the five patients given this treatment 
developed an acute paranoid reaction which began one to four days 
after medication treatment and resolved one to five days after 
methyl testosterone was stopped. All developed fearful delusions. 
In none of the five patients was there mo re than the usual degree 
of nuisance side effects that usually accompany imipramine treatment. 
The cause of the paranoid syndrome is uncertain. Testosterone, 
I ike oestrogen is taken up by the brain discretely86 and appears to 
h h .. f h d . 87 en ance t e activity ate nora renerglc system . This might 
account for an enhanced antidepressant response although how it would 
account for paranoid reaction is uncertain. 
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It is suspected by Prange that the paranoid reaction is dose 
related. It seems possible that the use of smaller doses of 
methyl testosterone would avoid paranoid symptoms and enhance 
antidepressant response. 
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SECTION 6 
MATERIALS AND METHODS 
6.1 Metabol ism Reactions Involvi ng Isolated Rat Hepatocytes 
Isolation and Use of Liver Cel Is 
The technique described is based on 1 iver perfusion with 
collagenase after removal of Ca 2+ by preperfusion with a chelator. 
Moderately high yields of viable, single hepatocytes with a 
smooth spherical appearance and initially free of non-parenchymal 
cells wereobtained. 
The Test Animals 
Albino female rats were used as the test animals. The animals 
were between 6 and 7 months old and weighed 200 ±20 g. Animals 
from a common source and stock were used since strain differences 
have been reported to be related to differences in drug metabol ising 
67 
enzymes Rats were allowed food and water ad librtumsince Kato 
88 ~~ . observed that starvation increased the metabol ism of drugs. 
Gas Mixture and Solutions 
All solutions were bubbled with carbogen gas (95% O2, 5% C02) 
and were heated to 37°C prior to use. The same gas mixture was used 
during perfusionof the 1 iver and incubation of the hepatocytes. 
Three different buffers we re used consecutively. All chemicals 
used were of analytical grade. 
HANK BUFFER CONCENTRATE 
NaCJI. 80 g 
KCJI. 4 g 
MgSO,.7H20 2 g 
tla2HPO, . 2H,-0 0,6 9 
KH,-PO, 0,6 9 
Distilled H20 to 1 i tre 
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HANK SOLUTION 
Hank Buffer Concentrate 
NaHC0 3 
Penici II in [Benzyl- 3 g (5 X 
Disti lied H2O 
HerES [s i gma No H 3375] 
FIRST PERFUStON FLUID - BUFFER A 
Hank Solution 
Albumin (B.S.A. Sigma) 
EGTA (Sigma E 3251) 
SECOND PERFUSION FLUID - BUFFER B 
Hank Solution 
Co II agenase 
Ca C£2.2H20 
10- 6 I E) in 100 m£] 
ISO m£ 
3 9 
34.2 mg 
100 m£ 
100 mg 
58.8 mg 
25 m£ 
525 mg 
2.5 m£ 
222 m£ 
750 mg 
[Collagenasemust be produced by Boehringer Mannheim from Clostridium 
histalyticum-Iyphal ized] 
BUFFER C - KREBS-HENSELE I T BUFFER 
H2 O 785 m£ 
NaC£ (16.09%) 200 m£ 
KC£ (I . 10%) ISO m£ 
KH2PO, (0.22M) 25 m£ 
MgSO,.7 H20 (2.74%) 50 m£ 
CaC£2. 2H 20 (0.12M) 100 m£ 
Bubble with carbogen. Dissolve 9.71 9 NaHC0 3 in I lit re dis till ed 
water and bubble with carbogen. Mix the two 'solutions. Store in a 
dark flask in a refrigerator. 
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INCUBATION MEDIUM 
Krebs Henseleit Buffer 
HEPES 
200 mil, 
0.75 g 
All solutionsshouldbe at a pH 7. 4andcould beadjusted with 1 M 
NaOH. Albumin lowers the pH. 
TRY PAN BLUE SOLUTION 
Trypan Blue 
Krebs Henseleit Buffer 
Distilled H2 0 
HEPES 
Albumin 
Mix, and set aside stirring overnight. 
in a .test tube. Freeze for later use. 
be microfine Flukon AG 93590. 
Perfusion Apparatus 
0.32 g 
100.0 mil, 
98.0 mil, 
0 . 6 g 
4.0 g 
Fi Iter. Place 0.99 mil, 
Trypan Blue to be used mu st 
Figure 17 depicts the 1 iver perfusion system. The buffer 
reservoirwas a 6 cm wide glass beaker that was thermost.atted to 3rC. 
A plastic rack consisting of two vertical tubes with a horizontal 
bar at the top and a tightly fitted screen with openings 1 x 1 mm 
wide in the bottom, was placed in the beaker. In the horizontal bar 
was a notch in which the cannula could be fixed. The oxygenator was 
acyl inder 10 cm high and 1.5 cm wide with four openings: one inlet 
for the gas mixture, one inlet for the perfusate, one outlet 
connected to the cannula (and the li ve r) and one outlet for the gas 
and shunted perfusate (bypassing the 1 iver). The oxygenator also 
functioned as a bubble trap. The s tee 1 cannu I a had a smooth (f i led) 
tip and a shallow (filed) groove around the cannula at 0.4 cm above 
E 
u 
<:> 
<:> 
carbogen 
l 
fig. I Z 
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the tip to secure the cannula in the portal vein. The cannula 
permitted a flow of 100 m~/min with pressure used. The various 
parts were connected with Teflon tubing and the dead volume in the 
system (oxygenator and tubing) was 50 m~. The gas inlet of the 
oxygenator was connectedtoa gascylinder with a pressure regulator 
with the centrifugal pump (Stuart) giving a constant flow rate 
(200 mi /min) . The pressure in the oxygenator was dependent on the 
flow capacity of the shunt, which was regulated by the gas flow, and alsu 
by a screw clamp appl ied to the shunt; that iS,the flow through the 
cannula could be varied from a few drops per minute to 100 m~/min 
by changing the gas flow. 
Surgical Procedure 
The rats were anaesthetized with ether and maintained. The peritoneal 
cavity was opened by a mid ventral incision. Hepa r i n (500 un its in 
O. 1 m~) was injected in the caval vein. A loose 1 igature was 
appl ied around the portal vein; an obI ique incision was then made in 
the mesenteric part of the vein, and the cannula was i mmediately 
inserted. The cannula was first fixed with a clamp and then secured 
with the 1 igature. The perfusate flow rate was then adjusted to let 
the liver resume normal shape . The 1 iver was excised by first 
removing the stomach and intestine in one piece,fol lowed by 1 iberation 
of the 1 iver from the diaphagm, and, finally with the rat in a ti lted 
position,by cutting the dorsal 1 igaments. The time from the 
insertion of the cannula until the 1 iver had been fr eed was less 
than 2 minutes. 
Perfusion and Washing Procedure 
The perfusion was started ~ situ with buffer A. To avoid 
perfusing bubbles into the 1 iver, the buffer was permitted to drip 
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out of the cannula before cannulation of the vein. A sign of 
adequate perfusion was that the 1 iver cleared immediately 
and completely. When the liver had been freed from the body, it 
was immersed in the buffer in the reservoir and the cannula was 
fixed to a horizontal bar. After 4 minutes of perfusion wit h 
buffer A, after all the haemoglobin had been removed, the plastic 
rack with the 1 iver was removed from the reservoir beaker and the 
oxygenator wa s almost emptied of perfusate by compressing the shunt. 
The rack was then placed in another beaker containing buffer B. 
Buffer B was recirculated for approximately 6 minutes. f..t the end 
of perfusion the 1 iver appeared swol len and pale, but no blebs 
were seen on the surface. The 1 iver was then immersed in 100 m~ 
incubation medium (in a wide 150 m~ capacity, low beaker), the 
capsula was cut open and the cells were dispersed with a pair of 
scissors by gentle stirring movements. Within 2 min utes, at 
ambient temperature,the dispersed cells were filtered through 
cotton gauze to remove connective tissue and clumps of cells. The 
filtrate was collected in a beaker 7 em wide. ,Within 2-3 minutes 
at ambient temperature, the cells settled to form a loose pel let 
and the supernatant was removed by aspiration. The volume of the 
pellet (approximately 10 m~) was estimated with a pipette and the 
eel Is (200-300 x 10 6 ) were counted in a haemocytometer chamber, 
using the white cell divisions. 
Viabil ity of Isolated Hepatocytes 
Cell viabil ity was routinely estimated by trypan blue staining 
prior to experi ments. 
Trypan Blue Exclusion Test 
The number of viable cells in each batch was estimated by 
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counting a suspension that had been diluted 100 fold in trypan 
blue solution. Within 5 minutes 1-2% of the eel Is were stained. 
This indicated that mo re than 90% of the cells we re stil I viab le. 
Incubation Procedures 
Incubations were started immed iately after isolation of the 
hepatocytes by diluting the sedimented cells in the incubation 
medium to final concentration of I - 3 X 10 6 cells/m~. This was 
done at ambient temperature, and the cells were never chil led be low 
this temperature. 
6. I • I The Effect of PremarinRon the "etabol ism of Antidepressive 
Imipramine using Hepatocytes and HPLC as Detection Apparatus. 
Controlled metabol ic reactions were carried out using rat isolated 
hepatocytes. Reaction vessels allowed low concentration of imipramine 
with and without Premarin: 
METHOD AND MATERIAL 
Apparatus 
High Performance Liquid Chromatography - Model Varian 8500 
Absorbance Detector 
Recorder 
Varian Aerograph R 254/280 nm UV Detector 
Varian Aerograph R CDS I I I 
Injector Varian Aerograph R High Pressure Septumless 
liquid Chromatography Injector 
Column:- C,a reversed phase column 39 mm x 30 em 
~ Bondapak. Water Association 
Additiona l equipment 
50 m~ Round bottomed flaskes 
Buchi apparatus Model 
250 m~ centrifuge tubes (poly propylene) 
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15 m~ conical pyrex centrifuge tubes 
Reagents and Standards 
All reagents were reagent grade (A.R . ) unless otherwise 
specified. 
Hexane UV grade 
Methanol HPLC grade 
Acetonitrile UV grade 
Isoamyl alcohol 
Pentane sulfonic acid (Pic B-5, 5 mmole/l itre, water association) 
Distilled water 
Mobile phase - Methanol/acetonitrile/phosphate buffer (0,1 mol/l itre 
pH 7,6) 41/15/44 by volume . 
pH was adjusted to 6,5 by dropwise addit ion of concentrated sod ium 
hydroxide or glacial acetic acid. The mixture was filtered through 0,45 
~m membrane filter under negative pressure. 
METHOD 
a) Preparation of hepatocytes as described earl ier. 
b) Metabol ic incubation. 
50 m~ round bottomed flasks were used. The order of additions 
was kept constant to prevent variations. 
Reaction vessels 
Imipramine HC~ (5 x 10- 2 M) 
Premarin" ( 5 x 10- 2 M) 
Hepatocytes ( X 10 6 cells/m~) 10 m~ 
2 
10 m~ 
3 4 
20 ~~ 
10 m£. 10 mt 
The final concentration of Premarin R and imipram i ne was 
This concentration was decided on as it was shown that antidepressives 
. h h' h . 89 are tOXIC to rat epatocytes at 19 er concentrations 
Incubation was al lowed for 10 min at 37°C in round bo ttomed flasks 
fitted on a standard taper distillation adaptor for four flasks which 
was rotated (10 rpm) on a rotary evaporator (Buchi). The evaporator 
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was positioned so that axes of rotation deviated 45° from the water 
surface and 50 that the flasks dipped down in the thermostatted water. 
To ensure adequate oxygenation during the incubation, carbogen gas 
was appl ied continuously to the surface of the incubation medium 
through the central vacuum exit of the evaporator. 
Enzymatic processes were stopped using I m~ 10% trichloroacetic 
acid which precipitated the protein. Thereafter, extraction was 
performed. The liquid-I iquid extraction methods are much simpler and 
more suitable for routine appl ications, as the recoveries of the 
tricycl ic drugs were found by others to be highly variable when a 
standard extraction/evaporation/reconstitution procedure was used. 
The more manipulations the procedure involved, the less reproducible 
it was. 
Reproducibi I ity was acceptable when the tricycl ic bases were 
simply extracted from alkal inized serum into hexane/isoamylalcohol 
(99/1) and re-extracted into a smal I volume of dilute hydrochloric 
acid. An al iquot of the aqueous acid was injected directly into the 
chromatograph, circumventing the evaporation step, which apparently 
was responsible for much of the observed variabil ity in recoveries. 
Use of relatively selective extract solvents combined with 
re-extraction of the basic amines into dilute acid removes most 
acidic and neutral interfering substances and leads to a sufficiently 
'clean' extract that requires no further purification. It was found 
90 by others ,that the solvent systems hexane/isoamylalcohol (99/1) 
presented the best compromise with respect to extraction efficiency 
and selectivity. Higher concentrations of isoamyl alcohol 
increased the background interference in the blank; lower 
proportions resulted in significant extraction losses of some of the 
tricycl ic amines. 
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The concentration of sodium hydroxide used to alkal inize 
the serum sample was cr iti cal for optim ium recovery; an excess 
decreased the recovery of the tricycl ic amines. 
Technique Used for Assay Procedure 
Tricyclic drugs and their metabolites in serumareusually 
measured by gas 1 iquid chromatography or high-performance 1 iquid 
chromatography (HPLC). Gas 1 iquid chromatography methods generally 
require a lengthy clean up procedure to el iminate interference from 
endogenous sample constituents, resulting in varia ble extraction 
91 , 92 losses and rendering them too cumbersome fo r routine cl inical use . 
89 93 ln most published HPLC methods . 1 iquid so l id-
chromatography (normal phase) on sil ica columns is used, wi th an 
al iphatt.c amine in the eluent to decrease chemisorption which causes 
peak tail ing. This leads to early deterioration of column 
efficiency owing to gradual dissolution of the si 1 ica packing at pH 
value about 7. Also the predominantly hydrophil ic endogenous 
plasma components and extraneous polar substances in the crude extracts 
have a high affinity for the polar packing materials,causing 
background interferences and necessitating long intervals for column 
92 
recovery in between injections or heated column compartments 
For these reasons the use of reversed phase HPLC is preferred for 
cl inical routine appl ications. 
The technique used for this assay of tricycl ic antidepressants 
and their me tabol ites is a modified me thod which uses a r eversed 
9, phase column . 
Ext raction Procedure 
1. 10 m£ of serum was transferred i n to a 250 m£ polypropylene 
c~ntrifuge tube (50 m£ tubes would have been preferred, however, no 
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head or tubes were available for MSE centrifuge that was 
used and internal standard was added . The solution was 
alkal inized to pH 14 by adding sufficient volume of 1,5 mol/I itre 
sodium hydroxide, and 10 mi hexane/isoamyl alcohol (99/1) was also 
added. 
2. The solution was rotated and mixed for 5 minutes; gentle 
agitation prevented any emulsion forming during this step. 
3. It was then centrifuged for 6 minutes at 500 x g (± 1800 rpm 
using MSE high speed centrifuge), and 9 m£ of the organic ( top) 
phase transferred into a 15 m£ conical centrifuge tube. 
4. 200 U£ of 0,1 mol/litre HC£ was added. The mixture was shaken 
for 10 minutes and centrifuged for 4 minutes at 500xg. 
5. After discarding the organic phase, . IO u£ of the aqueous acidic 
phase was injected into chromatograph using the fol lowing instrument 
se tt ings. 
Flow rate 
Detector 
Sensitivity 
90 m£/hr 
UV 250 nm 
Perkin-Elmer Recorder - Range 10 
and Varian CDS I I I - 8 
The peaks that resulted were recorded on recorder paper. Substrate 
disappearance was measured andthis was compared to internal standard , and 
a ratio of substrate height and internal standard height was measured 
and calculated. Metabol ite formation was' not measured, as in 
hepatocytes especially, further metabol ism occurs, e.g. by various 
conjugations. 
CHROMATOGRAPHIC CONDITIONS 
Stationary Phase 
To avoid the problems assoc iated wi th normal phase sil ica 
column s in routine analysis of crude plasma extracts i.e. excessively 
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long retention of polar constituents, necessitating long column 
recovery times in between injections, a c-18 bonded reversed phase 
column was used. 
Mobile Phase 
Water/methanol and water/methanol/acetonitrile mixtures were 
tested as mobil e phases in the pH r ange of 3-7 by others90 • They found 
that while some of the drugs could be separated under these conditions, 
the selectivity factors were inadequate especially for separating the 
tertiary amines from their secondary bases. Also, the peak shapes 
of the longer retained compounds we re not symmetrical, because of 
ionization of the amines in acidic and neutral solutions. Add it ions 
of a base (ammonia, ethylamine or propyl amine) to elution solvent did 
improve the peak shape by supressing ionization but resolution was 
poor and column efficiency quickly deteriorated owing to channel ing 
caused by gradual dissolution of the sil ica packing at the unfavourable 
pH. 
To el iminate the problems associated with ionization of the 
tricycl ic amines and to get their resolu tion at a pH below7 to ensure 
reasonable column I ife, the paired-ion technique was used. Pentane 
sulfonate (Pic B-5 water association) was used as a counter ion. 
Symmetrical peak shapes were obtained by using the solvent 
me thanol/acetonitrile/phosphate buffer (41/15/44). The phosphate 
buffer was prepared wi th water that contained 5 mmol pentane sulfonate. 
The pentane sulfonate was prepared by diluting Pic B-5 associated 
waters with litre of distilled water. 
Ef fect of pH 
A reported and actual finding was that the single mos t crit ical 
fuctor influencing the resolution of a tertiary and secondary amine 
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of identical fused-ring structure is the pH of the solvent system. 
At pH value <5 the tertiary compounds will not be separated from 
their secondary compounds. All the tricycl ic antidepressive 
tertiary amines wi II be separated at pH 6,2 to 6,5. At higher pH 
the separation increases but also the p~aks themselves which result. 
are reduced in symmetry. 
Detection in the Ultraviolet 
The absorption maxima of tricycl ic amines reported are about 
235 nm for doxepin, 240 nm for nortriptyl ine, and amitriptyl ine, 250 nm 
for imipramine and desipramine, 229 nm for dothiepin, Z5Z 11m for 
chlorimipramine and 250 nm for trimipramine. 
RESULTS 
Metabolism did occur, but P.remarinRdid not inhibit metabo l ism. 
Figs.1B.1 9 show spectra whe re the internal standardwas chlori mip ramine 
HCl, and the effect Premari~had on the substrate peak height. I t can 
R be clearly seen, that the presence of Premarin did not significantly 
affect the substrate height. 
CONCLUSION 
Results were surprising, as reports have shown that in women taking 
conjugated oestrogens these have interacted with imipramine9S A possible 
explanation is that a lower affinity for the rat cytochrome P-450 for 
Pre ma rinR may exist when comparing it to i mipra mine, since most of the 
oestrogens in Prema rinRare conjugated. 
A spectral study was done to see what effect PremarinRand 
ethinyl oestrad iol '·Jould have on the Ks value for imipramine HCl 
6.2 Spectral Techniques for Detection of Competitive Inhibition of 
Binding to Cytochrome p-450 between Two Substrates which el ici t 
the Same Type of Spectral Changes 
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IS 
IMP 
DESIMP 
I01JR. 
,. 
Figure 18. HPLC Spectrum of Imipramine HCR. (IMP) Metabol ised 
l1ajor Metabol ite is Desimipramine ( DES IMP) 
Internal Standard (1.5.) Chlorimipramine HC R. 
Figure 19. 
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IS 
IMP 
DES IMP 
HPlC Spectrum of Imipramine HC ~ (IMP) Metabol ised in 
the presence of PremarinR (I x 10-' M) 
Major Metabolite is Oesimipramine (OESIMP) 
Internal Standard (I.S.) Chlorimipramine HC .e. 
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Th is technique studies the spectral interaction with cytochrome 
P-4S0 and determines the Ks value . Ks value s are again determined 
when saturable amounts of competitive inhibito rare present. An 
increase in Ks value will indicate that a competition for cytochrome 
P-450 does exist. 
Mi~rosomes we re used instead of hepatocytes as special facil ities 
were necessary to use hepatocytes, such as frequent stirring. The 
apparatus available could only accommodate mi crosomes. 
PREPARATION OF RAT LIVER MICROSOMAL FRACTION 
Method used was that of Cinte et al. (197216. 
Chemicals 
Phosphate buffer, pH 7,4 prepared from KHzPO, and NazHPO,.2H zO 
0,25 M Sucruse 
1,15% KCt 
0,9% NaCt 
Ca.Ct z .2HzO 
All reagents used were analytical reagents grade. All so lu tions 
were stored in a refrigerator. 
All glassware used was thoroughly washed and rinsed in hot wa ter, 
then soaked in chromic acid for 24 hours. After this, glassware was 
rinsed three times in distilled water and dried in an oven at 75°C. 
This cleaning procedure was necessary to ensure that the glassware 
was scrupulously clean to prevent contamination of the hepatic 
microsomal preparation. 
Sacrificing the Animals 
Animals were sacrificed by a blow on the head with a metal bar. 
To prevent ci rcadian variation in hepatic mic rosomal activity, rats 
were sacrificed at the same time every morni ng between 09hOO to 09h15. 
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Once the animal had been sacrificed, the I iver was quickly excised 
and weighed. Once the I iver had been removed all operations we re 
performed between 0°C-4°C, to prevent degradation of the enzymes. 
When the I iver was removed, care was taken not to cut any of the 
lobes, since any damage would interfere with perfusion of the liver. 
Since haemoglobin would interfere with spectral examination of 
cytochrome p-450, it was removed from the I iver by perfusion with 
0,9% NaC2 until the I iver became I ighter in colour 97 A 25% w/v 
I iver homogenate was always prepared (Ig I iver and 3 volumes sucrose); 
thus after perfusion the I iver wa s placed into 3 volumes of cold 
0,25 M sucrose solution and minced into smal I pieces with a clean 
pair of scissors. 
Tissue Homogenization 
After the I iver had been minced, it was homogenized in a Thomas 
tissue homogenizer. 
The steel rod of the teflon pestle was attached to an electric 
drill which allowed the teflon pestle to be rapidly rotated while in 
the glass homogenizer. The electric drill was connected to a rheostat, 
so that the speed could be controlled. To homogenize the tissue, 
the glass homogenizer tube was moved up and down relative to the 
pestle. This action and rapid rotation caused disintegration of the 
tissue and disruption of the cells, yielding a homogenate 
consisting of diluted cell sap , intracellular particles and some 
unbroken cells. 
centrifugation. 
These components were separated by fractional 
The following precautions we re observed during tissue 
homogenization. The I iver was minced as finely as possible, since 
smal I pieces of tissue homogenize easier than large pieces, also to 
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prevent overheating of the tube and subsequent enzyme destruction . 
The homogenizing tube was kept cold throughout the process by 
means of ice in a beaker, wi th the tube moving up and down in the 
cold water. 
Centrifugation 
The homogenate was transferred to two plastic centrifuge tubes 
and placed in a MSE 18 High Speed Centrifuge at 4°C. 
The differential centrifugation was started at 4000xg (5,8 x 10 3 
revolutions per minute) for 10 minutes to al low all debris and 
nuclei to sediment, this was followed by 20 min at 10 OOOxg (9,2 X 10 3 
revolutions per minute) to allow mitochondria to sediment. Two steps 
were employed since fewer microsomes were trapped by sedimenting . 
part i c 1 es. The supernatant 1 iquid was poured into a clean measuring 
cyl inder and made up to 40 mt with cold 0,25 M sucrose. This 1 iquid 
was then adjusted to a final concentration of 8 rna cad2 • 
The Ca 2+ makes aggregates of the endoplasmic reticulum membranes 
and thus causes the microsomes to sedi .ment in 15-20 min at a force of 
27000xg (15500 revolutions per min) [without Ca 2 + one would have to 
apply a force of 105000x9 for an hourl. The resulting microsomal 
pel let was washed by resuspending it in an equal volume of 1,15% KC t 
and resedimented at 27000xg. The new pellet was washed to remove 
excess Ca 2 +, which may interfere with subsequent metabol ic tests. 
The f inal microsomal pel let was rehomogenized in phosphate 
buffer of pH 7,4 and the preparation appropriately diluted for 
studies. 
Spectral studies were best done when the protein 
concentration was approximately 1 mg/l mt. 
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Determination of Microsomal Protein. 
Miller's Modified Lowry Protein Determination 98 
The coloured complex for med in this assay is only proportional 
to the protein concentration in the range of 50 to 200 ~g/m~. Thus 
the microsomal suspension had to be diluted accordingly. 
Method 
B.S.A. of known water content was used as the standard protein 
and a cal ibration curve was constructed using standard solution of 
protein in place of the protein test solution. All determinations 
were performed in dupl icate. I m~ of the protein solution to be 
tested (al iquot protein solution was di luted a 100 fold) or I m~ 
of water for the blank was added to I m~ of the copper reagent, 
mixed and allowed to stand for 10 minutes at room temperature. 
3 m~ of di luted Folin-Phenol reagent was added and immediately 
mixed well. The tubes were heated for 10 minutes at 50°C in a water 
bath and the optical density was read at 450 nm. The values 
obtained from the calibrationcur vewere corrected by the dilution 
factor. All reagents were freshly prepared from stock solutions. 
Fol in-Phenol reagent:- 5 m~ of Fol in-Phenol reagent was diluted 
with 50 m~ of distilled water. 
Copper Reagent:- (from the following stock solutions) I m~ 1% 
copper sulphate; I m~ 2% sodium tartrate; 20 m~ 10% sodium carbonate 
in 0,5 M NaOH. 
A Beckman DB 25 uv spectrophotometer was used to measure 
absorbance. 
Results of Microsomal Protein Determination 
Strength of solution (mg/m~) 
Absorbance (nin) 
0,05 
0,65 
0,10,150,2 
1,22 1,695 2,17 
Discussion 
Miller's modified Lm'ry protein assay was used as workers like 
Albrdo4 who investigated various methods for microsoma l protein 
determination found it the most accurate. 
The colour formed is thought to be due to a complex between the 
alkal ine copper phenol reagent and the tyrosine and tryptophan 
residues of the protein. 
6.2. I The Determination of Spectral Dissociation Constant (Ks) for 
Imipramine Hydrochloride and the In Fluence that Saturable 
Amounts of PremarinRand Ethinyl Oestradiol has on the 
Imipramine Ks Value 
A method is described which allows 
a) The determination of compounds used, binding to give a type I 
spectrum. 
b) The estimation of dissociation constant for type I binding. 
c) The detection of competitive inhibition of binding to cytochrome 
p-450 between two substrates which elicit the same type of spectral 
change. 
The simultaneous binding of two compounds to the same site on 
cytochrome p-450 may be examined, provided that both compounds show 
a type I binding spectrum. The spectral effect observed on simultaneous 
additions to microsomal suspension cannot be separated. 
Materials and Methods 
The biochemical methods , such as preparation of liver microsomes, 
have already been described. 
A Beckman Acta MVI ultraviolet spectrophotometer was set up as 
deta i led in the ope rat i ng book let. 
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Wavelength scanned 500-360 nm (Tungsten source) 
Period selector switch 2 
Span control 0.02 
Mode switch set at OB. Serve sl it position 
SI it program selector set on program position 
A.Determination of Cytochrome P-450 
Reagents 
Method 
Prepared hepatic microsomal suspension 
Carbon monoxide 
Na,S,04 
Carbon monoxide difference spectra of cytochrome p-450 were run 
on a Beckman Acta M~I Spectrophotometer in the range from 500 nm to 
360 nm. 
All procedures were carried out at room temperature. 
I. 2 mt of microsomal suspension was placed into each of two 
matched cuvettes of I cm optical. path length. 
2. A basel ine was prepared with the aid of a set of potential 
adjustments every 20 nm from 500 nm to 360 nm. 
3. The microsomal suspension from each cuvette was pooled and the 
solution reduced with a few mil I igrams of fresh Na 2S204. since 
exposure of powdered Na2S204 to air and moisture results in 
its decomposition to an inactive form. If a strong pungent 
odour of bisulfide is apparent the sample of Na2S 204 should be 
discarded. 
4. 2 mtwas pipetted out into the sa mple cell and the remaining 2 mt 
returned to the reference cuvette. 
5. The sample cuvette was then treated with carbon monoxide by 
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bubbl ing the gas through for one minute. 
6. The spectrum was then recorded from 500 nm to 360 nm. 
7. Each spectrum was then traced out and suitable adjustments 
for irregularities in the basel ine effected. 
8. The amount of cytochrome P-450 can be calculated from 
optical difference (450-490 nm) and a mo lar extent ion 
1 - 1 99 coefficient of 91 nM- cm 
x~--------------~x 
B. 2 mt of the microsomal suspension was pipetted into precisely 
matc hed cuvettes i.e. identical I ight path, and placed in the 
sample and reference compartments of the scatter transmission 
sect ion of the ins trument. The cuvettes were placed in the 
optical path with their frosted rather than their clear faces in 
the I ight beams. This ensures a more uniform scattering of light 
through the sample thereby giving a better statistical representation 
of the contents of the cuvettes 97 It was found that di lute 
microsomal suspension (0,5-1,0 mg/m~gave a mo re satisfactory 
basel ine. A baseline was prepared with the aid of a set of 
potential adjustments every 20 nm from 500 nm to 360 nm. 
The spectral changes were produced by titrating smal I amounts of 
imi pramine hydrochloride using a Hamilton micro litre syringe. 
Where large vo lume additions were involved an equal volume of 
distilled water was added to the reference cuvette. The spectrum 
was then recorded from 500 nm to 360 nm. A number of spectra 
for imipramine were performed so as to establ ish a Ks value (Ks 
is defined as the concentration of reactan t that res ults in a 
spectral change of 50% of the theoretical maximal spectral 
change obtainable). 
Thereafter, further Ks va lues for imiprami ne were determined. 
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. " However, in these experiments saturating concentrations of Premarln 
or ethinyl oestradiol were present which had been determined spectrally 
previously. The reference cuvette had also been saturated and on a 
straight basel ine generated before addition of imipramine to the 
sample cuvette. If competition for the same cytochrome P-450 
binding site existed, then an increase in the Ks value would result. 
Each spectrum was traced out and suitable adjustments for 
irregularities in the basel ine effected. Ks values were determined 
by the double reciprocal plot of spectral changes (I/I'.IA) vs substrate 
concentration (I/[S]). 
The cytochrome p-450 levels were also determined for each 
batch of microsomes used. This was done . as spectral changes 
resulting from substrate interaction with cytochrome P-450 are 
dependent not only on the concentration of substrate but also on the 
concentration of cytochrome p-450 in the microsomal suspension 
Results 
Imipramine hydrochloride, Premarin"and ethinyl oestradiol all 
showed type I spectra. The Ks value for imipra;nine hydrochloride 
determined after three determinations was 0,125 x 10- 6 M. This value 
compared favourably with that determined by von Bohr et al. wh i ch 
was 0,22 x 10- 6 M. 
Figure 20 shows the shift of Ks value with the presence of 
saturable amounts of Premarin"and ethinyl oestradiol. It also shows 
the effect that varying concentrations of cytochrome P-450 have. 
Concentration is expressed as m~ moles. 
The results show that ethinyl oestradiol caused a greater shift, 
resulting in a high Ks value for imipramine hydrochloride . This 
would indicate more imipramine hydochloride was required to obtain the 
same spectra as compared to when Premarin"was used. 
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K2 = Binding constant of imipramine hydrochloride in the presence of saturable 
amounts of Premarin R = [ 2,5 J jJm 0,4 x 
K, = Bind i ng constant of imipramine hydrochloride in the presence of sat urable 
amounts of ethinyl oestradiol = [0,75J jJm = 1,33 x 
Fig. 20 Graphic Determination of Spectral Binding Constant Ks of Imip ramine 
Hydrochloride. 
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Conclusion 
This method used was on ly a comparative technique to determine 
which of the two inhibitors would cause a greater ~s shift for 
imipramine hydrochloride. • R A muc h sma ller shift when Premarln was 
used may account for the reason why Premari~did not significant ly 
inhib i t imipramine hydrochloride metabol ism"henhepatocytes were 
used. 
The lower value when PremarinRwas used indicates that PremarinR 
did no t bind as strongly as ethiny l oestrad iol to cytochrome P-450. 
Based on th is observation, one could conclude that ethinyl oestradiol 
may be a stronger metabol ic inhibitor than Premarin~ On this assumption 
metabol ic reactions were carried out, however, this time microsomes 
instead of hepatocytes were used, because of the simpl icity of obta ining 
microsomes as compared to hepatocytes, therefore lending itself to a 
more rap id laboratory procedure. 
6.3 Determination of the effect of Ethinyl Oestradiol on the Metabol ism 
of Tricycl ic Antidepressives 
Controlled metabol ic reactions were carried our using rat liver 
microsomes. Reaction vessels contained varying concentrations of 
ethinyl oestradiol and the extent of metabol is m of the imipramine in 
each was determined. 
Methods and Material 
Materials used have been described already. 
Method 
a) The microsomes were prepared as described earl ier. 
b) Metabol ic Incu bation 
50 m9. round bottomed flasks were used. The following compounds were 
added to each f las k and the order of additions was kept constant to 
prevent variations. 
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The fol lowing solutions were prepared:-
5 mM MgCl. and 0,005 mM MnC £./0,2 ml 
NADP 1,4 mg/ lsocitric Acid 2,5 mg/0,2 ml 
Antidepressives I x 10-' M 
Ethinyl Oestradiol I x 10-' M, 2 X 10- 3 M. 
Reaction Vessels 
2 3 4 
200 111 200 III 200 »1 
2. Disti lied Water ad qs 2,0 ml 
3. NADP/lsocitric Acid 200 III 200 111 200 111 200 III 
4. Antidepressives 20 111 
5. Ethinyl Oestradiol 
a) x 10- " M 200 W1 
b) 2 x 10- 3 M 300 w1 
c) 2 X 10- 3 M 100 1'1 
6. Microsomes I ,0 m1 1,0 m1 1,0 m1 1,0 m1 
7. I soc i trate Dehydrogenase 20 III 20 III 20 111 20 »1 
The final concentration of antidepressives in reaction vessels was 
I x 10- 4 M. 
The final concentration of ethinyl oestradiol was in 
vessel 2 = 
vessel 3 = 3 X 10- 4 M 
vessel 4 
The NADPH gene rating system functions in the fol lowing way 
++ 
D.L Isocitric Acid + NADP Mg K I . A'd + H+ + CO + NAOPH ++ ) a etog utarlc CI 2 
Mn 
Isocitrate Dehydrogenase 
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Incubation was allowed for 10 minutes at 37°C in round bottomed 
flasks fitted onto a standard disti llation adaptor for four flasks 
which was rotated at 10 rpm on a rotary evaporator (Buchi). The 
evaporator was positioned so that the axis of rotation deviated 45°C 
from the water surface, so that the flask dipped down into the 
thermostatted vJ3ter. To ensure adequate oxygenation during the 
incubation,carbogen gas was appl ied continuously to the surface of 
the incubation medium through the central vacuum exit of the 
evaporator. 
Theenzymaticprocesswasstopped using 1 m9. 10% trichloroacetic 
acid, which precipitated the protein. 
standards were then added. 
The respective internal 
Choice of Internal Standard for HPLC 
An internal standard must be similar in structure to the compound 
being studied. In this case a different tricycl ic antidepressive was 
used, then the one under investigation. 
Before any tricycl ic antidepressive could be used as the 
internal standard, it was necessary to run a metabol ic reaction. The 
spectra. were recorded using HPLC. The spectra influence the choice, 
as an internal standard must not appear where other peaks are present. 
Also the standard should be eluted quickly, so as to reduce the time 
between each run. Another factor to be considered is the 
concentration of internal standard to be used. It was found that the 
tricycl ic antidepressives varied as far as extraction efficiency was 
concerned. Therefore concentrations were determined experi mentally 
so that a 11 the peaks fe 11 in the requ ired sca 1 e. The table shows 
which internal standards were used and concentrations used. 
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Internal Std. Conc n • Volume used 
Imipramine HC~ Chlorimipramine HC~ 0, I g/IO M 10 WV2 m~ 
Amitriptyl ine HC~ Doxepin HCx. x 10- 2 M 10 pQJ 2 m~ 
Chlorimipramine rlC~ Doxepin HC~ x 10- 2 M 10 WU 2 m£. 
Trimipramine Maleate Doxepin HCQ, x 10- 2 M 10 lJV 2 mx. 
Doxepin HCx. Amitriptyl ine HCx. x 10- 2 M 40 wVZ m£. 
Dothiepin HC ~ Amitriptyl ine HC£. x 10- 2 M 40 lJ£/2 m£ 
Extraction Procedure 
I. 2 m£ of serum was transferred into 250 m£ polypropylene 
centrifuge tubes. The solution was alkal inized to pH 14 by 
adding 600 lJ£ 5,0 mol/I itre sodium hydroxide, and 10 mx. 
hexane/isoamyl alcohol (99/1) was also added 
2 . This was rotated and mixed for 5 mlnutes; gentle rotation 
prevented any emulsion forming during this step. 
3. It was centrifuged for 6 minutes at 500 xg and 9 m£. of the 
organic (top) phase was transferred into a IS m£ con ical 
centrifuge tube. 
4. 200 11£ of 0, I mol/I i tre HC£ was added. The mixture was shaken 
for 10 minutes and centrifuged for 4 min at 500 xg. 
5. After discarding the organic phase the aqueous acidic phase was 
injected into HPLC chromatograph The injection volumes did 
vary, the following volu me s were used:- Imipramine HC£., Ami tryptyl i ne 
HC£ and Doxepin HCx. and Dothiepin HC£., injection volumes we re 10 mL 
Tri mip ramine maleate and chlorimipramine HCx. injection volumes 
were 50 mx.. Larger Volumes of trimipramine maleate and 
chlorimipramine HC£. were used because the extraction efficiency of 
these compounds is lower. 
Instrument Settings 
Flow rate 
Sensitivity 
Detector uv 250 nm 
240 nm 
252 nm 
250 nm 
235 nm 
229 nm 
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90 mQ./hr 
Perkin-Elmer Recorder - Range 10 and 
Varian COS I I I - 8 
f i Iter Imipramine HCQ. 
Ami triptyl ine HCQ. 
Chlorimipramine HC£' 
Trimipramine maleate 
Doxepin HC£' 
Dothiepin HC £' 
The peaks that resulted were recorded on recorder paper. 
Substrate disappearance was measured. This was compared to 
internal standard and a ratio of substrate height and internal 
standard heights was measured and calculated. 
Chromatographic conditions were the same as for hepotocytes, 
as covered in section 5. I. 
Results 
Figures 21a, 21b, 21c, 21d, 22a, 22b, 22c, 22d, 23a, 23b, 23c, 
23d, 24a, 24b, 24c, 24d, 25a, 25b, 25c, 25d, 26a, 26b, 26c, 26d, show 
representative spectra of the tricycl ic antidepressives under study, 
wi th thei r varying internal standards. The spectra show the influence 
that varying concentrations of ethinyl oestradiol had on the metabol ism 
of the tricycl ic antidepressives . The metabol ites were labelled in 
cases where they could be identified. 
Fr om the spectra, substrate peak heights and internal standard pea k 
heights were measured. From these measurements, the ratios of substr a te 
peak heights to internal standard peak heights were calculated and 
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tabulated as shown in Table 6 Three metabol ic reactions were 
performed. The ratios were then expressed as a percentage metabol ic 
activity, where the smallest ratio represented maximal metabol ism. 
Using these values, a graphical representation was made as shown in 
figure 27. The various graphs clearly show that as the concentration 
of ethinyl oestradiol increased the metabol ic activity of rat microsomes 
decreased. 
Conclusion 
From these results it showed clearly that ethinyl oestradiol 
s t rongly inhibited the metabolism of various tricycl ic antidepressives 
and this supports the concept put forward earl ier that ethinyl 
oestradiol would be a stronger metabol ic inhibitor than Premarin R• 
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IS IMP 
Il'SIMP 
Figure 21a HPlC Spectrum of Imipramine 
HC.t (IHP) Metabolised 
Major Metabol ite Desimipramlne (DES IMP) 
Internal Standard (1.5.) Chlorimipramine 
HC~ 
IMP 
IS 
Figure 21b HPLC Spectrum of Imipramine HGt 
(IMP) Metabolised In the presence of Ethinyl 
Oestradiol (I x 10-' H) 
Internal Standard (1.5.) Chlorimlpramlne HC~ 
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IMP 
IS 
OESIMP 
Figure 21c HPLC Spectrum of Imipramine HC £ (IMP) Metabol i sed 
in the presence of Ethinyl Oestradiol (I x 10-4M ) 
Major Metabol ite is Oesimipramine (OESIMP) 
Internal Standard (1.5.) Chlorimpramine HC £ 
-102-
IMP 
IS 
DESIMP 
Figure 21d HPLC Spectrum of Imipram i ne HC £ (IMP) 
Metabol ised in the presence of Ethinyl Oestradiol 
(3 x 10-' M) 
Major Metabol ite i s Desi mipramine (DESIMP) 
Internal Standard (1.5 .) Chlor imipramine HC £ 
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IS 
x 
AMT 
NORT 
Figure 22a HPLC Spectrum of Amitriptyl ine 
HCt (AMT) Metabol ised 
Major Metabol ite is Nortriptyl ine (NORT) 
Internal Standard (1.5.) Doxepin HCt 
IS 
AMT 
x 
Figure 22b HPLC Spectrum of Amitriptyline HCl 
(AMT) Metabol ised in the presence of Ethinyl 
Oestradiol (I x 10-' M) 
Internal Standard (1.5.) Doxepin HCt 
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IS 
x 
Figure 22c HPLC Spectrum of Amitriptyline HC 2 (AMT) Metabol ised in 
the presence of Ethinyl Oestradiol (I x 10-' M) 
Internal Standard (1.5.) Doxepin HC2 
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IS 
AMT 
x 
10pi 
~ 
Figure 22d HPLC Spectrum of Amitriptyl ine HC£ (AMT) Metabol ised in the 
presence of Ethinyl Oestradiol (3 x 10- 4 M) 
Internal Standard (1.5.) Doxepin HC£ 
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RIHP 
IS 
x 
Figure 23a HPLC Spectrum of Trlmlpramlne 
Maleate (TRIHP) Hetabollsed 
Internal Standard (1.5.) Doxepln HC! 
TRIHP 
IS 
Figure 23b HPLC Spectrum of TrimipramineMaleate 
(TRIHP) Metabolised in the presence of Ethinyl 
Oestradiol (I x 10-' M) 
Internal Standard (1.5.) Doxepin HCe 
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TRIHP 
IS 
x 
figure 23c HPlC Spectrum of Trimlpramlne 
Haleate (TRIHP) Hetabollsed In the presence 
of Ethinyl Oestradiol (I x 10-' H) 
Internal Standard (1.5.) Ooxepln HC1 
TRIHP 
IS 
x 
Figure 23d HPLC Spectrum of Trlmlpramine Haleate 
(TRIHP) Hetabollsed In the presence of Ethinyl 
Oestradiol (3 x 10-' H) 
Internal Standard (1.5.) Ooxepin HCI 
CHLIMP 
DES 
CHLIMP 
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IS 
Figure 24a HPCL Spectrum of Chlor-Imlpramlne 
HCt (CHLIHP) Metabolised 
Internal Standard (1.5.) Doxepln Het 
IS 
CHLlHP 
Figure 24b HPLC Spectrum of ehlor-imipramine 
HCt (CHLlMP) Iletabolised in the presence of 
Ethlnyl Oestradiol (I x 10- 3 H) 
Internal Standard (1.5.) Doxepin HCt 
50~t 
+ 
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IS 
CHLI HP 
Figure 24c HPLC Spectrum of 
Chlorimipramine He£. (CHlIHP) metabol ised 
in the presence of Ethinyl Oestradiol 
( I x 10-') 
Internal Standard (IS) Doxepin HC~ 
IS 
CHLI HP 
Figure24d HPLC Spectr um of Chlorimipramine 
HCi (CHLIHP) metabol ised in the presence of 
Ethinyl Oestradiol (3 x 10- ' M) 
Internal Standard (15) Doxepin Hn 
50~~ 
f 
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IS 
DOTH 
Figure 25a HPLC Spectrum of Dothiepln 
HCt (DOTH) Metabolised 
Internal Standard (I.S.) Amltriptyl ine 
He! 
DOTH 
IS 
lOut 
• 
Figure 25b HPCL Spectrum of Dothiepin HC t (DOTH) 
Metabolised in the presence of Ethinyl Oest radiol 
(1 x 10-' M) 
Internal Standard (I.S.) Ami tr ipty l ine HC t 
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DOTH 
Figure 25c HPLC Spectrum of Dothiepin 
HCl (DOTH) Hetabolised in the Presence 
of Ethinyl Oestradio l (I x 10-' II) 
Figure 25d 
Metabo I i sed 
(J x 10-') 
DOTH 
IS 
HPlC Spectrum of Oothiepin HCl (DOTH) 
in the Presence of Ethinyl Oest ra dio l 
Internal Standard (I,S.}Amitriptyline 
He.!. Internal Standard (1.5.) Amit rip ryl ine HC't 
-112-
IS 
DOX 
Figure 26a HPLC Spectrum of Ooxepin 
HC~ (DOX) Metabol ised 
Inte rna l Standards (I.S) Amitriptyline HC~ 
IS 
DOX 
Figure 26b HPLC Spectrum of Doxepin 
He£. (DOX) Metabol ised in the presence of 
Ethinyl Oestradiol (I x 10-J H) 
·I n~ternal Standards (I.S) Arnilriptyli rle HCR. 
-I 13-
15 
DOX 
Figure 26c HPLC Spectrum of Doxepin He! 
(oox) Metabol ised in the Presence of 
Ethiny) Oestradiol (I x )0- ' 11) 
Internal Standard (I.S.) Amitriptyline 
HCR. 
15 
DOX 
Figure 26d HPLC Spectrum of Ouxe:pin He;. 
(DOX) Metabol i sed i n the Presence of 
Ethiny) Oestradiol (J x 10-' M) 
Internal Standard (1 .5 .) Am itripyline 
HCR. 
Concentration of Drugs used 
in Metabol ic Reaction 
A 
Imipramine HC.Q. + Ethinyl 
Oestradiol 
a I x 10-- M -
b I x 10-- M I X 10-' M 
c I X 10-- M 3 X 10-- M 
d I X 10-- M I X 10-- M 
B 
Amitriptyl ine HC.Q. + Ethinyl 
Oestradiol 
a I x 10-- M -
b I X 10-- M I X 10-' M 
c I x 10-- M 3 X 10-' M 
d I x 10-- M I x 10-' M 
C 
Doth i ep i n HC.Q. + Ethinyl 
Oestradiol 
a I x 10-' M -
b I X 10-- M I x 10-' M 
c I x 10-' M 3 X 10-' M 
d I x 10-' M I X 10-- M 
0 
Doxepin HC.Q. + Ethinyl 
Oestradiol 
a I x 10-' M -
b I X 10-' M I x 10-' M 
c I x 10-- M 3 x 10-' M 
d I x 10-' M I x 10-- M 
E 
Chlorimipramine HC.Q. + 
Ethinyl Oestradiol 
-, 
-a 
b 
c 
d 
x 10M 
x 10-- M 
x 10-' M 
X 10-' M 
I x 10-' M 
3 X 10-' M 
I x 10-' M 
F 
Trimipramine Maleate + 
Ethinyl Oestradiol 
a I x 10-' M 
b I X 10-' M I X 10- ' M 
c I x 10-' 11 3 x 10-' M 
d I x 10-' M I X 10- ' M 
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TABLE 6 
Rat io 
A 
0,73 
1,46 
1,26 
I ,21 
0,50 
I , 13 
0,89 
0,75 
0,80 
I ,35 
I ,21 
I , 00 
0,59 
I , 04 
0,93 
0,90 
I I 0,30 I 0,85 
I 
0,78 
0,59 
I I , 13 
I I ,94 
, I ,51 
1 1,42 
I 
of 
, 
Peak 
B 
1,72 
2,20 
2,07 
2,03 
0,40 
0,95 
0,80 
0,68 
0,82 
I ,42 
1,22 
1,07 
0,28 
0,98 
0,91 
0,77 
0,27 
0,85 
0,75 
0,65 
1,00 
1,87 
1,56 
I ,29 
Heights % Metabol ic Act ivity 
I 
I 
I , 
I 
, 
I 
! , 
I 
I 
I , 
I 
I , 
! 
I 
I 
I 
I 
C A 
I ,79 100 
2,20 a 
2, II 28 
2,03 35 
0,38 100 
1,04 a 
0,80 38 
0,67 60 
0,79 100 
1,50 a 
I ,24 25 
0,99 I 64 
I 
• I 
I 
! 
I 
0,34 I 100 
0,93 j a 
0,80 24 
0,66 I 31 
i 
! 
, 
i 
I 
i 0,26 100 
0,87 I a 
I 0,77 ; 13 
0,64 48 
0,99 100 
1,93 a 
1,60 53 
1,24 64 
I 
I , 
B 
100 
a 
22 
35 
100 
a 
27 
50 
100 
a 
33 
58 
100 
0 
10 
30 
100 
a 
17 
34 
100 
a 
36 
66 
I 
I 
I 
I 
I 
I 
I 
I , 
I 
C 
100 
a 
20 
41 
100 
a 
36 
56 
100 
a 
37 
71 
100 
a 
22 
46 
100 
a 
16 
38 
100 
a 
35 
73 
Fig . 27 
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6.4. A Study of the Antichol ine r gic Activity of Nomifensine, 
Tricycl ic Antidepressives and their Derivatives 
It has been noted that side effects experienced by people taking 
antidepressives are characteristic of antichol inergic activity. The 
aim of this study is to determine if these compounds possess anti-
chol inergic activity, the order of affinity for and possible structure 
activity relationship with respect to antichol inergic effect. 
Methods and Material 
Metrohn flat bed recorder 
Isotonic e lec tronic transducer 
Organ ba th 
Circulating water pump to maintain temperature . 
Reagents 
Tyrode solution 
NaCQ, 8 9 
KCQ, 0,2 9 
MgCQ,2 0,2 9 
CaCQ,2 0,2 9 
NaH2PO, 0,05 9 
NaHC0 3 1,0 9 
Glucose 1,0 9 
Dis till ed water to 1 1 i tre 
The Tyrode solution was freshly prepared each day. Tv·,1o orga n 
baths were used, both attached to a flat bed recorder, via an isotonic 
electronic transducer. A rat jujenum was prepared and then 
susp ended in Tyrodes at 37°C and aerated. 
A cumulative dose response curve was drawn using carbachol as 
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antagonist. Once two similar curves were obtained, the organ was 
washed, and the dntagonist was added for 7 minutes so as to reach 
equil ibrium with the tissue. Thereafter, another dose response 
curve was drawn and the shift of the curve was measu red, and by means 
of tables the log affinity constants for the antagonists were 
determined. 
Severa l determinations were made. 
Results 
AI I the drugs tested showed antichol inergic activity. The 
table shows the decreasing order of affinity for the chol inergic 
receptors in the rat j uj enum. 
n pA2 
Amitriptyl ine 6 8,0 ± 0, I 
Protriptyl ine 6 8,0 ± 0, I 
Tri mip ramine 6 7,9 ± 0,2 
Oothiepin 6 7,8 ± 0,2 
Nortriptyl ine 6 7,7 ± 0,2 
Chlorimipramine 6 7,6 ± 0,2 
Imi pramine 6 7,6 ± 0,2 
Desipramine 6 6,8 ± 0,2 
Nomifensine 6 5,3 ± 0,3 
The dibenzocyc lo heptane derivatives we re found to be more potent 
than the dibenzazepine derivatives. In the dibenzocycloheptane 
series substitutionof C-II withS (Oothiepin) red t:ced potency. On the 
other hand methylation of the te rminal nitrogen increased act ivity. 
The parent compounds possess a greater antichol inergic affinity as 
compared to their metabol ites. 
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Conclusion 
Maximum antagonistic activity depends on three factors. 
I. Tricycl ic skeleton 
2. Side chain 
3. The substitution on the terminal amine 
I. The skeleton. Dibenzocycloheptane appears to confer optimal 
conformation and an alteration such as Dothiepin leads to a decrease in 
affinity. 
2. Side chain. In the propyl si de chain the double bond does not 
appear to be of particular significa nce comparing amitriptyl ine with 
protriptyl ine. 
A substituent on the S C atom does, however, influence the 
affini ty sl ightly , comparing trimipramine wi th imipramine. 
3. Terminal amine. On the terminal amine of the side chain, 
especially when combined with dibenzazepine skeleton, the methyl 
substitution plays an important role. 
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DISCUSSION 
The first experiments used rat hepatocytes as the metabol ic 
agents and Premarin R as the inhibitor of metabol ism. The results 
showed that Premarin R did not influence the metabol ism of imipramine 
when using hepatocytes. However, what did come to I ight was how 
difficult it was to obtain hepatocytes. A long and extremely 
difficult surgical technique was required, and a watchful eye was 
needed to keep the rat sedated. The actual metabol ic reactions were 
simple, as was the extraction method, although care was needed not to 
mix the extraction phases too much as an emulsion would form and this 
resulted in a reduced extraction of the parent compound and its 
lipophil ic metabolites. A High Pressure Liquid Chromatograph was the 
detection apparatus. Using this apparatus it was quick and easy to 
detect the parent molecule and its metabol ites. However, the instrument 
was very sensitive, hence the mobile phase had to be made carefully under 
recommended conditions, as a sl ight variation, for example, in pH, caused 
a marked difference in the shape and separation of the peaks. Although 
the actual runs for results were quick, a lengthy preparation was needed 
as well as thorough cleaning afterwards to ensure maximum column life. 
A closer investigation was needed to explain why Premarin R did not 
inhibit the metabol ism of imipramine. It could be because Premarin R 
possesses .someconjugated oestrogens, therefore it is in a form which has 
a lower affinity than imipramine for the metabol ic sites. Thus the 
body can get rid of Premarin R much more easily than imipramine, as it is 
al ready in a more water soluble form. 
It therefore became necessary to use an unconjugated oestrogen and 
ethinyl oestradiol was chosen. Before another metabolic reaction was 
-120-
performed, spectral studies of imipramine, ethinyl oestradiol and 
P . R . d remarln were carrie out. This was to establ ish if they al I show 
the same kind of spectra and if so, this would indicate that they 
occupy the same metabol ic binding sites. Rat microsomes were used 
as the spectrophotometer avai lable did not lend itself to hepatocytes. 
The results showed that they all had a type I spectrum. Next was the 
determination of the saturation point of the microsomes using ethinyl 
oestradiol and Premarin R and then to see what influence these would 
have on the spectrum of imipramine. It was evident that more 
imipramine was required in both cases to obtain the same spectrum. 
More imipramine was used when comparing ethinyl oestradiol to Premarin R 
A graphic plot was done and this showed that ethinyl oestradiol greatly 
affected the affinity of imipramine for the microsomes when compared 
to Premarin R. This, therefore, suggests that ethinyl oestradiol has 
a greater inhibitory effect than Premarin R. 
Further metabol ic reactions were carried out using microsomes as 
the metabol ic agents, as these were easier and less expensive to 
prepare. The same detection technique was used as for hepatocytes. 
Varying concentrations of ethinyl oestradiol were used to inhibit 
metabol ism. Results distinctly showed that inhibition had taken 
place with a number of the tricycl ic antidepressives used. 
In addition a study of the anticholinergic activity of Nomifensine, 
tricyclic antidepressives and their derivatives was performed on a rat 
jujenum. This technique was slow and simple, although great care was 
needed when titrating the volumes of agonists and antagonists into the 
organ bath. Here results showed that the parent compounds had a 
greater affinity for the chol inergic receptors than their metabol ites. 
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These results support the theory that the increased anticholinergic 
side effects experienced, aredue to an inhibition of metabol ism of 
tricycl ic antidepressives, hence an increased level of parent compound 
in the blood stream; which has in tt1rn ~ ~reater ant1chol Inergic 
affinity. 
A possible solution to the problem is to prescribe a newer 
antidepressive which has no or very little anticholinergic effect, or 
to choose a tricyclic antidepressive metabol ite which has a lower pA2 
value compared to the parent molecule, such as desipramine. 
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